Female reproductive system disorder
MONDO:0002263A disease involving the female reproductive system.
Also known as: disease of female reproductive system, disease or disorder of female reproductive system, disorder of female genital system, disorder of female reproductive system, female reproductive disease, female reproductive system disease, female reproductive system disease or disorder, female reproductive system disorder
3079 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 622 trials in this tab.
-
New vaccine could stop recurring yeast infections in their tracks
⭐️ VACCINE ⭐️ OngoingThis study tests a new vaccine called Candi5V in 251 women who get frequent yeast infections (at least 3 per year). The vaccine is designed to train the body's immune system to fight Candida fungus. Researchers will check if it's safe and if it reduces future infections.
Phase: PHASE1, PHASE2 • Sponsor: LimmaTech Biologics AG • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:10 UTC
-
New drug cocktails show promise against tough endometrial cancer
Disease control OngoingThis study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer cell growth or helping the immune system attack tumors. The goal is to see if these combinations can slow or stop the can…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could a triple therapy beat cervical cancer?
Disease control OngoingThis phase 3 trial tests whether adding the drug triapine to standard radiation and cisplatin improves survival in women with advanced cervical or vaginal cancer. About 450 participants receive either standard treatment or standard treatment plus triapine. The study aims to see i…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy plus radiation may keep endometrial cancer from returning
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard radiation therapy can better prevent cancer recurrence in people with newly diagnosed, early-stage endometrial cancer that has a specific genetic feature (mismatch repair deficiency). About 164 parti…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo may outperform chemo for returning ovarian cancer
Disease control OngoingThis study tests whether olaparib (a targeted drug) alone or combined with cediranib (which blocks tumor blood vessels) works better than standard platinum chemo for women whose ovarian, fallopian tube, or peritoneal cancer has returned after initial treatment. About 579 particip…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy plus chemo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis phase III trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced (stage III or IV) or recurrent endometrial cancer. About 800 participants received either the combo or chemo alone. The …
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancer mutation in first human trial
Disease control OngoingThis study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy drug nivolumab tested against tough cervical cancers
Disease control OngoingThis phase II trial tests the drug nivolumab (Opdivo) in 26 women with cervical cancer that has persisted, returned, or spread despite prior treatment. Nivolumab is an immunotherapy that helps the body's immune cells recognize and attack cancer. The study measures how many patien…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New cocktail of drugs could offer hope for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests whether adding immunotherapy (atezolizumab) and/or a blood vessel blocker (bevacizumab) to standard chemo (pegylated liposomal doxorubicin) works better for ovarian cancer that has stopped responding to platinum drugs. About 444 women with recurrent ovarian, fall…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New combo therapy shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tests whether adding the drug ipatasertib to standard hormone therapy (megestrol acetate) works better than hormone therapy alone for people with recurrent or metastatic endometrioid endometrial cancer. About 96 participants with grade 1 or 2 cancer will receive either…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Zapping ovaries: could a quick procedure replace daily pills for PCOS infertility?
Disease control OngoingThis study tests a device that uses heat to ablate (destroy) a small part of the ovary in women with polycystic ovary syndrome (PCOS) who have trouble getting pregnant. The goal is to restore ovulation without needing daily medication. About 195 women will be randomly assigned to…
Phase: NA • Sponsor: May Health • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New cancer drug AB598 enters first human tests
Disease control OngoingThis early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug combo aims to outsmart Platinum-Resistant ovarian cancer
Disease control OngoingThis study tests whether combining two drugs, cediranib and olaparib, works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum-based chemo. About 582 women will be randomly assign…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New cancer drug AB801 enters human safety testing
Disease control OngoingThis early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…
Phase: PHASE1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Engineered immune cells target Hard-to-Treat cancers in new trial
Disease control TerminatedThis study tests a new treatment using specially engineered immune cells (TROP2 CAR-NK) delivered directly into the abdomen. It is for people with ovarian cancer that no longer responds to platinum chemotherapy, as well as certain rare ovarian and pancreatic cancers. The goal is …
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Experimental drug combo aims to outsmart recurrent ovarian cancer
Disease control OngoingThis early-phase trial tests whether adding an experimental drug called berzosertib to standard chemotherapy (carboplatin and gemcitabine) can better treat ovarian, peritoneal, or fallopian tube cancer that has returned and spread. The study involves 35 adults with platinum-sensi…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Cancer drug safety tracked over years in ongoing study
Disease control OngoingThis study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…
Phase: PHASE3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Could chemo keep uterine sarcoma at bay? new trial seeks answers
Disease control TerminatedThis Phase II trial is testing whether a combination of two chemotherapy drugs, doxorubicin and trabectedin, can help prevent uterine leiomyosarcoma from coming back after surgery. The study enrolls 48 patients with high-risk, early-stage disease who have had their tumor fully re…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new targeted drug called MLN0128 combined with bevacizumab (Avastin) in about 50 patients whose glioblastoma or other solid tumors have returned or not responded to standard treatment. The main goal is to find the safest dose and see how the body ha…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope: drug before surgery may shrink ovarian tumors
Disease control OngoingThis study tests whether the drug olaparib, given before surgery, can shrink tumors in women with recurrent ovarian cancer that has come back after at least 6 months. About 71 participants will receive either olaparib or standard chemotherapy before surgery. Researchers will meas…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to outsmart resistant cancers
Disease control OngoingThis early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…
Phase: PHASE1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo tested for tough cancers
Disease control OngoingThis early-stage trial tests a new drug called remzistotug, alone or with other cancer drugs, in 152 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is not yet known if the drug will sh…
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Ovarian cancer combo shows promise in maintenance therapy
Disease control OngoingThis phase IV trial tests whether the drugs olaparib and bevacizumab, taken together after initial chemotherapy, can help prevent ovarian cancer from coming back in women with a specific genetic marker (HRD-positive). About 190 participants who have already responded to first-lin…
Phase: PHASE4 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug cocktail aims to prevent rare melanoma recurrence
Disease control OngoingThis phase II trial tests whether adding cabozantinib to the immunotherapy drug nivolumab can prevent mucosal melanoma from returning after surgery. About 101 patients with resected mucosal melanoma will receive either nivolumab alone or nivolumab plus cabozantinib. The study aim…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immune army targets ovarian cancer in new trial
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests a personalized cell therapy for advanced ovarian cancer. About 20 women will receive immune cells engineered to recognize and attack their cancer. The main goals are to check safety and see if the treatment shrinks tumors.
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Targeted therapy boost for aggressive uterine cancer under study
Disease control TerminatedThis phase 3 trial tests whether adding targeted drugs (trastuzumab and pertuzumab) to standard chemotherapy can better shrink tumors in people with HER2-positive endometrial cancer. The study plans to enroll 360 participants with various stages of the disease. However, the trial…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new treatment called IVS-3001, which uses a patient's own immune cells (T cells) engineered to target a protein called HLA-G found on some solid tumors. The study involves 31 adults with advanced solid tumors that have not responded to standard trea…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New immunotherapy combo targets rare cancers left behind by progress
Disease control OngoingThis phase 2 trial tests a combination of two immunotherapy drugs, domvanalimab and zimberelimab, in people with five types of advanced rare cancers (peritoneal mesothelioma, gestational trophoblastic tumor, anaplastic thyroid carcinoma, neuroendocrine tumors, and thymic carcinom…
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can a blood injection reboot ovaries? small trial tests PRP for fertility
Disease control OngoingThis study tests whether injecting a woman's own platelet-rich plasma (PRP) into the ovary can help restore function in women with premature ovarian insufficiency (early menopause). 35 women under 40 will receive PRP in one ovary and a saline placebo in the other. The main goal i…
Sponsor: ART Fertility Clinics LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo shows promise for Tough-to-Treat uterine cancer
Disease control OngoingThis phase 2 trial tests two drugs—niraparib and TSR-042 (dostarlimab)—in 51 women with recurrent endometrial cancer that has progressed after platinum chemotherapy. The goal is to see if these drugs can shrink or stabilize tumors. Niraparib blocks a protein that helps cancer cel…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control OngoingThis trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…
Phase: PHASE1 • Sponsor: Toray Industries, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental combo targets Chemo-Resistant cancers
Disease control OngoingThis study tests an experimental drug called NEO-201 combined with the immunotherapy pembrolizumab in adults with advanced solid tumors that no longer respond to chemotherapy. The trial focuses on lung, head and neck, cervical, and uterine cancers. Researchers aim to find a safe …
Phase: PHASE1, PHASE2 • Sponsor: Precision Biologics, Inc • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New oral drug aims to tackle Hormone-Driven cancers
Disease control OngoingThis study tests an experimental drug, imlunestrant, in people with advanced or metastatic breast cancer that is estrogen-receptor positive (ER+), as well as certain other cancers like endometrial cancer. The drug is given alone or combined with other anticancer therapies. The ma…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New antibody drug takes on advanced tumors in first human trial
Disease control OngoingThis early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…
Phase: PHASE1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Cancer patients who respond to avelumab can keep taking it in this Follow-Up study
Disease control OngoingThis study offers continued access to the cancer drug avelumab (and sometimes other drugs) for people with advanced cancers like lung, ovarian, or bladder cancer who are already seeing benefits from a previous Pfizer-sponsored trial. About 77 participants will be followed for saf…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo targets tumors in patients with organ failure
Disease control OngoingThis early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for recurrent ovarian cancer
Disease control OngoingThis phase II trial tests whether adding the immunotherapy tremelimumab to the PARP inhibitor olaparib works better than olaparib alone for women with platinum-sensitive recurrent ovarian, fallopian tube, or peritoneal cancer. About 61 participants will receive either olaparib al…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental CAR-T therapy takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new treatment for people with advanced solid tumors that have a specific marker called CLDN6. The treatment uses specially engineered immune cells (CAR-T cells) that target CLDN6, sometimes combined with a genetic booster (RNA-LPX) to enhance their …
Phase: PHASE1 • Sponsor: BioNTech Cell & Gene Therapies GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to outsmart Platinum-Resistant ovarian cancer
Disease control OngoingThis phase 2 trial tests whether adding an experimental drug called M6620 (berzosertib) to standard gemcitabine chemotherapy helps women with ovarian, fallopian tube, or primary peritoneal cancer that came back after platinum-based treatment. About 70 participants will receive ei…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy after Chemo-Radiation shows promise for advanced cervical cancer
Disease control OngoingThis study tests whether the immunotherapy drug TSR-042 can help prevent cervical cancer from returning in patients with high-risk locally advanced disease who have completed standard chemo-radiation. About 134 women will receive TSR-042 as a maintenance therapy to see if it exte…
Phase: PHASE2 • Sponsor: Grupo Español de Investigación en Cáncer de Ovario • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to block cancer growth in RAS-Mutant tumors
Disease control OngoingThis phase II trial is testing whether combining two targeted drugs, palbociclib and binimetinib, can help people with cancers that have RAS mutations. The study includes patients with pancreatic cancer, ovarian cancer, and other solid tumors. Researchers want to see if the drug …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cancer drug candidate BG-68501 enters first human trials
Disease control OngoingThis early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New targeted therapy hopes to shrink Hard-to-Treat ovarian cancers
Disease control OngoingThis study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
High-Dose chemo with stem cell transplant tested against standard therapy for tough germ cell cancers
Disease control OngoingThis phase 3 trial compares two chemotherapy approaches for people with germ cell tumors that have returned or not responded to initial treatment. One group receives standard-dose chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP). The other receives high-dose chemothe…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy targets Hard-to-Treat recurrent cancers
Disease control OngoingThis early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for recurrent ovarian and endometrial cancers? drug tazemetostat under study
Disease control OngoingThis phase II trial is testing the drug tazemetostat in 62 patients whose ovarian or endometrial cancer has returned after prior treatment. The goal is to see if tazemetostat can shrink tumors or stop them from growing. Participants will receive the drug and be monitored for resp…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Weekly shot could replace daily needles for kids with growth disorders
Disease control OngoingThis study tests if a new growth hormone medicine (somapacitan) given once a week works as well as the standard daily growth hormone (Norditropin) for children who are very short due to being born small, or having Turner syndrome, Noonan syndrome, or unknown causes. About 412 chi…
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New combo therapy hopes to tame advanced cancers
Disease control OngoingThis early-phase trial tests several new drug combinations in people with advanced solid tumors (like stomach, ovarian, or liver cancer) that have spread and stopped responding to standard treatments. The goal is to find the safest dose and see if the drugs can help control the c…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Which antibiotic works best when water breaks early?
Disease control OngoingThis study tests two common antibiotics—erythromycin and azithromycin—in pregnant people whose water breaks too early (before 34 weeks). Both are given along with standard antibiotics. The goal is to see which combination helps delay delivery longer, giving the baby more time to …
Phase: PHASE3 • Sponsor: Inova Health Care Services • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Lifeline for cancer patients: continued access to promising drug olaparib
Disease control OngoingThis study offers continued treatment with the drug olaparib to people with ovarian or breast cancer who have already seen benefits from it in a previous study. The goal is to keep providing the drug safely while monitoring for any serious side effects. About 185 participants wil…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…
Phase: PHASE1 • Sponsor: Rondo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Promising drug cocktail targets Hard-to-Treat ovarian cancer
Disease control OngoingThis phase 2 trial is testing a combination of nab-sirolimus (Fyarro) and fulvestrant (Faslodex) in 37 people with recurrent low-grade serous ovarian cancer. The goal is to see if the drugs can shrink tumors or stop them from growing. Participants receive the drugs intravenously …
Phase: PHASE2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Weekly shot may replace daily needles for short stature kids
Disease control OngoingThis study tests a new once-weekly growth hormone medicine (somapacitan) against a daily one (Norditropin) in 62 children born small who remain short. The goal is to see if the weekly shot works as well and is safe. Children receive injections either once a week or once a day for…
Phase: PHASE2 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail targets Hard-to-Treat ovarian and uterine cancers
Disease control OngoingThis early-phase trial tests an investigational drug called RP-6306 alongside standard chemotherapy (carboplatin and paclitaxel) in 6 women with recurrent ovarian or uterine cancer that has a specific genetic change (TP53 mutation). The main goal is to find a safe dose and check …
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New triple therapy targets Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of three drugs—bintrafusp alfa, PDS01ADC, and entinostat—in adults with advanced HPV-related cancers (like cervical, anal, or throat cancer) or certain colon cancers that haven't responded to standard treatment. The goal is to find a safe dose and s…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for hard-to-treat endometrial cancer: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called sacituzumab govitecan in 50 people with endometrial cancer that has returned or not responded to platinum chemotherapy. The drug works by delivering chemotherapy directly to cancer cells. The main goal is to see how many patients' tumors shrink or d…
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug aims to control advanced cervical cancer
Disease control TerminatedThis phase 2 trial tests a drug called lorigerlimab (MGD019) in 47 people with advanced cervical cancer that has spread or come back. The goal is to see if the drug can help control the cancer and improve survival. Participants receive the drug through an IV. The study is current…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Immune-boosting drug shows promise in ovarian cancer fight
Disease control OngoingThis early-phase study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced ovarian, fallopian tube, or primary peritoneal cancer. About 18 people with stage III or IV cancer will receive the combination. The main goal is to me…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New hope for Hard-to-Treat ovarian cancer: Rina-S faces off against standard chemo in major trial
Disease control OngoingThis study tests a new drug called Rina-S against standard chemotherapy for people with ovarian cancer that has stopped responding to platinum-based treatments. About 530 participants will be randomly assigned to receive either Rina-S or one of four approved chemo drugs. The goal…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Precision radiation may cut side effects in cervical cancer
Disease control OngoingThis study tests online adaptive radiotherapy, a type of radiation that adjusts in real-time to target cervical cancer more precisely. By using smaller treatment margins, doctors hope to reduce side effects while still effectively treating the tumor. The trial involves 30 adults …
Phase: PHASE1, PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New cocktail aims to stall ovarian cancer
Disease control OngoingThis Phase 3 trial tests whether adding durvalumab (an immunotherapy) and olaparib (a targeted drug) to standard chemotherapy and bevacizumab can help people with newly diagnosed advanced ovarian cancer live longer without their cancer growing. About 1,400 participants are involv…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New pill shows promise for Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…
Phase: PHASE1 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for rare ovarian tumors: targeted drugs under study
Disease control OngoingThis phase 2 trial is testing several targeted drugs in people with rare types of ovarian cancer that have come back or not gone away. The drugs are chosen based on specific biomarkers in each patient's tumor. The goal is to see if these treatments can shrink or control the cance…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Immunotherapy combo shows promise in preventing High-Risk uterine cancer return
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (with or without radiation) after surgery can help prevent high-risk endometrial cancer from coming back. About 990 participants who had surgery to remove their uterus and ovaries will r…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Could a diabetes drug fix period problems in teens with type 1?
Disease control ENROLLING_BY_INVITATIONThis study looks at whether dulaglutide, a drug used for type 2 diabetes, can help regulate menstrual cycles in adolescent girls with type 1 diabetes who have poor blood sugar control. Researchers will give some participants dulaglutide plus insulin, while others get only insulin…
Phase: PHASE1, PHASE2 • Sponsor: Ain Shams University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could a Pre-IVF pill boost baby chances for endometriosis patients?
Disease control OngoingThis Phase 3 trial tests whether taking Elagolix, a hormone-blocking drug, before IVF can increase live birth rates in women with endometriosis. About 97 women will receive either Elagolix or a placebo before their IVF cycle. The goal is to see if this pre-treatment improves the …
Phase: PHASE3 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Promising combo for Hard-to-Treat ovarian cancer never got off the ground
Disease control TerminatedThis study was designed to test whether a new drug called M4344, combined with the PARP inhibitor niraparib, could be safe and effective for women with recurrent ovarian cancer that had stopped responding to PARP inhibitors. The plan was to enroll women with advanced ovarian, pri…
Phase: PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Fibroid surgery Follow-Up drug trial pulled before it began
Disease control TerminatedThis study aimed to see if taking Myfembree (a combination pill) daily after fibroid removal surgery could delay the return of fibroids and improve quality of life. It was designed for premenopausal women with uterine fibroids who had surgery. However, the trial was withdrawn bef…
Phase: PHASE4 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo shows promise against advanced cervical cancer in early trial
Disease control OngoingThis study tests whether adding a new immunotherapy drug (cadonilimab) to chemotherapy before the usual chemoradiation can shrink tumors better in people with locally advanced cervical cancer. About 29 participants will receive the combination, then standard treatment. The goal i…
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could a simple shot replace IV drips for some cancer patients?
Disease control OngoingThis early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis phase II trial is testing a combination of two drugs—atezolizumab (an immunotherapy) and bevacizumab (a drug that cuts off blood supply to tumors)—in 110 women with advanced, recurrent, or persistent endometrial cancer. The goal is to see how many patients experience tumor s…
Phase: PHASE2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Engineered immune cells take aim at multiple cancers in early trial
Disease control OngoingThis early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …
Phase: PHASE1 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug cocktail aims to fight rare uterine cancer after chemo fails
Disease control OngoingThis study tests whether combining olaparib and temozolomide works better than standard drugs (trabectedin or pazopanib) for people with advanced uterine leiomyosarcoma that has spread or cannot be removed by surgery and has stopped responding to initial chemotherapy. About 74 pa…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New antibiotic vabomere tested in kids with tough UTIs
Disease control OngoingThis study tests the safety of an antibiotic called Vabomere in children aged 3 months to 12 years who have complicated urinary tract infections, including kidney infections. The children receive the medicine through an IV while in the hospital. Researchers monitor for side effec…
Phase: PHASE2 • Sponsor: Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New cancer drug IDE161 enters human testing
Disease control OngoingThis early-stage trial is testing a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the right dose, and get a first look at wheth…
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Blueberry compound may boost cancer treatment in small trial
Disease control OngoingThis phase II trial tests whether adding pterostilbene, an antioxidant found in blueberries, to the hormone drug megestrol acetate can better slow endometrial cancer growth before hysterectomy. About 44 patients will receive either megestrol acetate alone or with pterostilbene fo…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug cocktail aims to outsmart resistant ovarian cancer
Disease control OngoingThis Phase 2 trial tests two experimental drug combinations in 63 women with a specific type of ovarian cancer (BRCA-mutant or HRD-positive) that has worsened after prior PARP inhibitor treatment. Participants receive either tuvusertib plus niraparib or tuvusertib plus larteserti…
Phase: PHASE2 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for endometrial cancer: immunotherapy and targeted drug combo tested
Disease control OngoingThis Phase 3 trial tests whether adding the immunotherapy drug durvalumab and the targeted therapy olaparib to standard chemotherapy can help women with newly diagnosed advanced or recurrent endometrial cancer live longer without their cancer growing. About 805 participants will …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New robot could transform hysterectomy surgery
Disease control OngoingThis study is testing a new robotic system, the Medtronic Hugo™, for performing hysterectomies. It includes 70 patients with conditions like uterine fibroids, endometriosis, or certain cancers. The goal is to see if the robot is safe and can complete the surgery without switching…
Phase: NA • Sponsor: Medtronic - MITG • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New surgical technique aims to reduce cancer margins in vulvar dysplasia
Disease control OngoingThis study tests whether a surgery that uses frozen sections to guide removal (Frozen-Section Directed Excision) works better than the usual wide local excision for high-grade vulvar dysplasia. About 112 adults with confirmed high-grade dysplasia will be randomly assigned to one …
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for Platinum-Resistant ovarian cancer: targeted drug combo enters phase 2 trial
Disease control OngoingThis phase 2 trial tests whether combining bevacizumab (a drug that blocks blood vessel growth) with anetumab ravtansine (a targeted therapy) works better than standard paclitaxel chemotherapy for women with ovarian, fallopian tube, or primary peritoneal cancer that no longer res…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Experimental drug targets HER2-Positive tumors in multiple cancers
Disease control OngoingThis phase 2 trial tests an experimental drug called disitamab vedotin in people with advanced head and neck, lung, endometrial, or ovarian cancers that have a protein called HER2. The drug is designed to stick to cancer cells and kill them. Researchers want to see if it shrinks …
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail aims to stall ovarian cancer recurrence
Disease control OngoingThis Phase 3 trial is testing whether adding mirvetuximab soravtansine (a drug that targets a protein called FRα on cancer cells) to standard bevacizumab maintenance therapy can delay cancer progression in women with recurrent ovarian, fallopian tube, or peritoneal cancer. The st…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for brain metastases? drug niraparib tested in small trial
Disease control OngoingThis study tests the drug niraparib in 20 people whose cancer has spread to the brain or spinal cord. The goal is to see if the drug can shrink or control these tumors. Participants must have mild or no symptoms from their brain metastases and not need increasing steroids or seiz…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo targets recurrent ovarian cancer in small trial
Disease control OngoingThis phase 2 trial tests a new drug called SKB264, given by IV every two weeks, in 20 women with recurrent ovarian epithelial cancer. It also looks at how the antibiotic clarithromycin affects SKB264 levels in the body. The main goals are to see if the drug shrinks tumors and to …
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo shows promise for rare uterine cancer
Disease control OngoingThis study tests two drugs—olaparib and temozolomide—together in 23 people with advanced uterine leiomyosarcoma that has spread or cannot be removed by surgery. Olaparib blocks a protein that helps cancer cells repair themselves, while temozolomide damages cancer cell DNA. The go…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug duo shows promise against tough uterine cancer
Disease control OngoingThis study tested a combination of two drugs—mirvetuximab soravtansine and pembrolizumab—in 18 people with a specific type of uterine cancer (endometrial cancer) that had returned or persisted and was microsatellite stable (MSS). The goal was to see if the combo could shrink tumo…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug targets rare cancer mutation in early trial
Disease control OngoingThis early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…
Phase: PHASE1 • Sponsor: Atavistik Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug duo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with advanced, recurrent, or metastatic endometrial cancer. The goal was to see if the combo could slow or stop cancer growth. Cabozantinib blocks enzymes that help tumors grow, while nivolumab…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Fertility drug showdown: which combo helps women get pregnant faster?
Disease control OngoingThis study compares two common fertility treatments—letrozole alone versus clomiphene citrate plus tamoxifen—in 240 women with infertility due to ovulation problems. The goal is to see which approach leads to more ovulations and pregnancies. Participants will be monitored with ul…
Phase: PHASE3 • Sponsor: Sana'a University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can simple tools help cancer survivors live healthier?
Disease control OngoingThis study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill may keep endometrial cancer at bay longer
Disease control OngoingThis study tests whether the drug selinexor can help keep advanced or recurrent endometrial cancer from growing back after initial chemotherapy. About 276 adults whose cancer has a normal p53 gene and who responded to platinum-based chemo will receive either selinexor or a placeb…
Phase: PHASE3 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill targets hard-to-treat cancers with KRAS mutation
Disease control OngoingThis study tests an experimental drug called LY3537982 in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and shrinks tumors. About 540 participants with lung, colorectal, endometrial, ovarian, pancreatic, or bile …
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 women will receive one of s…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for advanced endometrial cancer: three-drug combos tested in major trial
Disease control OngoingThis study tested three different drug combinations in 349 people with advanced (stage III or IV) or recurrent endometrial cancer. The goal was to see which combination worked best at stopping the cancer from growing or spreading. Participants received either paclitaxel/carboplat…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for rare ovarian cancer: which chemo combo works best?
Disease control OngoingThis phase 3 trial tests two different chemotherapy regimens, with or without the targeted drug bevacizumab, as first treatment for a rare type of ovarian or fallopian tube cancer called mucinous epithelial cancer. About 50 patients with newly diagnosed or recurrent cancer will b…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug targets Hard-to-Treat cancers in major trial
Disease control OngoingThis study tests a new drug called raludotatug deruxtecan (R-DXd) in 200 adults with advanced or spreading solid tumors, including certain ovarian, cervical, endometrial, bladder, and kidney cancers. The goal is to see if the drug can shrink tumors or stop them from growing. Part…
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Weekly vs. Every-3-Weeks chemo: which works better for ovarian cancer?
Disease control OngoingThis phase III trial tested two different schedules of the chemotherapy drug paclitaxel (weekly vs. every three weeks) combined with carboplatin, with or without the targeted drug bevacizumab, in 692 patients with advanced ovarian, peritoneal, or fallopian tube cancer. The goal w…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo aims to unleash immune system against tough ovarian cancer
Disease control OngoingThis study tests whether a two-drug combination can help the immune system attack ovarian cancer that has returned after standard treatments. The drugs are E7777, which removes certain immune cells that block the body's defenses, and pembrolizumab, which reactivates cancer-fighti…
Phase: PHASE1, PHASE2 • Sponsor: Alexander B Olawaiye, MD • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental drug combo shows promise for Tough-to-Treat gynecologic cancers
Disease control OngoingThis early-phase study tested an oral drug called triapine added to standard chemotherapy (cisplatin) and radiation for people with advanced cervical or vaginal cancer. The main goals were to find the safest dose and check how well the body absorbs the drug. Twenty-one participan…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Drug cocktail shows promise in slowing return of ovarian cancer
Disease control OngoingThis phase 2 study tests whether combining two oral drugs, olaparib and cediranib, can help control recurrent ovarian, peritoneal, or fallopian tube cancer. About 70 participants with high-grade serous or endometrioid cancers are enrolled. The goal is to see if the combination ca…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-stage trial is testing a new drug called tuvusertib, given together with either lartesertib or avelumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body pr…
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug combo shows promise for Tough-to-Treat cancers
Disease control OngoingThis study tests whether combining two drugs—cediranib (which cuts off a tumor's blood supply) and olaparib (which blocks cancer cell repair)—works better than olaparib alone for people with certain ovarian, fallopian tube, peritoneal, or triple-negative breast cancers that have …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo therapy tackles cancer in HIV patients
Disease control OngoingThis early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug targets rare gene fusions in multiple cancers
Disease control OngoingThis phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New targeted drug shows promise for rare cancer mutation
Disease control OngoingThis early-stage trial tests a new drug, ALTA2618, in about 110 adults whose advanced solid tumors (like breast or endometrial cancer) have a specific genetic change called AKT1 E17K. The main goals are to check the drug's safety and find the right dose. Participants must have tr…
Phase: PHASE1 • Sponsor: Alterome Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New pill targets multiple KRAS mutations in Hard-to-Treat cancers
Disease control OngoingThis early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The d…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
MRNA cancer shots: new hope or hype?
Disease control OngoingThis early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab.…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for advanced cervical cancer: MK-2870 trial launches
Disease control OngoingThis Phase 3 trial compares a new drug, MK-2870, against standard treatments for people with recurrent or metastatic cervical cancer that has progressed after initial therapy. About 686 participants will receive either MK-2870 or a doctor-chosen standard treatment. The main goal …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Fewer trips to the hospital? new cervical cancer radiation trial aims to cut treatment time
Disease control OngoingThis study compares a shorter, higher-dose radiation schedule (hypofractionated) to the standard longer schedule for cervical cancer patients also receiving chemotherapy. The goal is to see if the shorter schedule is just as safe and effective, while reducing the number of hospit…
Phase: NA • Sponsor: Siriraj Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug cocktail shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis phase II trial tests whether adding ribociclib to a standard two-drug regimen (everolimus and letrozole) works better for people with advanced or recurrent endometrial cancer. About 90 participants will be randomly assigned to receive either the two-drug or three-drug combin…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control OngoingThis phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer,…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New cancer drug shows promise in early trial
Disease control OngoingThis early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Heated chemo during surgery may extend life in ovarian cancer relapse
Disease control OngoingThis study tests whether adding heated chemotherapy directly into the abdomen during surgery can help people with relapsed ovarian cancer live longer. About 415 adults whose cancer returned in the abdomen after initial treatment will take part. The approach aims to control the di…
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug duo aims to halt hard-to-treat endometrial cancer
Disease control OngoingThis early-phase study tests whether combining two drugs, DKN-01 and pembrolizumab, can help control advanced or recurrent endometrial cancer that cannot be cured with surgery or radiation. Eight adult women with this type of cancer will receive the combination. The main goals ar…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for advanced cervical cancer: drug trial targets remaining risk
Disease control OngoingThis study tests an experimental drug called volrustomig in 37 women with high-risk, locally advanced cervical cancer that hasn't gotten worse after standard chemotherapy and radiation. The goal is to see if the drug can help keep the cancer from coming back or spreading. Partici…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New HPV vaccine combo aims to fight Hard-to-Treat cancers
Disease control OngoingThis study tests an HPV vaccine (PRGN-2009) alone or with a drug called M7824 in people with HPV-positive cancers like cervical, anal, and throat cancers. The goal is to find a safe dose and see if the combination boosts the immune system's attack on tumors. The trial includes 39…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug combo shows promise in shrinking cervical tumors before surgery
Disease control OngoingThis phase 2 trial tests whether adding the immunotherapy drug QL1706 to standard chemotherapy before hysterectomy can improve outcomes for people with locally advanced cervical cancer. About 54 participants will receive three cycles of the combination, then surgery if the tumor …
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Ovarian cancer drug combo shows promise in slowing disease
Disease control OngoingThis study tested whether adding the drug olaparib to standard chemotherapy (paclitaxel and carboplatin) helps people with advanced ovarian cancer live longer without their cancer getting worse. It included 162 adults whose cancer had previously responded to platinum-based treatm…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to starve and attack tumors in advanced cancers
Disease control OngoingThis early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors like melanoma, colorectal, ovarian, and kidney cance…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…
Phase: PHASE1 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Weekly shot may replace daily growth hormone for turner syndrome kids
Disease control OngoingThis study tests a new long-acting growth hormone (lonapegsomatropin) given once a week, compared to the standard daily growth hormone shot, in 48 prepubertal children with Turner syndrome who have not had growth hormone before. The goal is to see if the weekly shot is safe and h…
Phase: PHASE2 • Sponsor: Ascendis Pharma Endocrinology Division A/S • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for rare ovarian cancer: Triple-Drug trial targets recurrent tumors
Disease control OngoingThis phase II trial is testing a combination of three drugs—darolutamide, leuprolide acetate, and exemestane—in 37 people with recurrent ovarian granulosa cell tumors. The drugs work by blocking hormones that may fuel tumor growth. The goal is to see if the combination can shrink…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental cocktail targets Hard-to-Treat cancers
Disease control TerminatedThis early-phase trial tests a new drug called ZEN003694, which blocks certain enzymes that help cancer grow, combined with two immunotherapy drugs (nivolumab and ipilimumab) that boost the immune system to attack cancer. The study includes 66 adults with advanced solid tumors, i…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Prolapse surgery showdown: which procedure wins?
Disease control OngoingThis study compares two common surgeries for uterine prolapse: a minimally invasive sacrocolpopexy and a vaginal hysterectomy with uterosacral ligament suspension. Researchers will track 300 women to see which surgery has fewer failures and complications from the patient's perspe…
Phase: NA • Sponsor: University Hospitals Cleveland Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo aims to outsmart Chemo-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new drug called peposertib combined with a standard chemotherapy (PLD) in people with ovarian or related cancers that have stopped responding to platinum-based treatment. The main goal is to find the safest dose and understand side effects. About 54…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo targets returned ovarian and uterine cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of two drugs, APG-1252 and cobimetinib, given together to people whose ovarian or endometrial cancer has come back. The drugs work by blocking proteins that help cancer cells survive and grow. The goal is to see if the combina…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Cancer-Fighting virus teams up with immunotherapy to tackle rare skin tumors
Disease control OngoingThis phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New targeted therapy shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests a drug called mirvetuximab soravtansine in people with a specific type of recurrent ovarian cancer that has high levels of a protein called folate receptor alpha. The drug delivers chemotherapy directly to cancer cells to try to slow or stop the cancer from growi…
Phase: PHASE2 • Sponsor: AGO Research GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug cocktail targets Hard-to-Treat tumors
Disease control OngoingThis early-stage trial tests a new oral drug called ceralasertib, given alone or with other cancer treatments like chemotherapy or targeted drugs, in 354 adults with advanced solid tumors that no longer respond to standard care. The main goal is to check safety and find the best …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New Antibody-Drug conjugate shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …
Phase: PHASE1, PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Drug combo shows promise in early ovarian cancer trial
Disease control OngoingThis early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …
Phase: PHASE1 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a simpler lymph node check replace major surgery for endometrial cancer?
Disease control OngoingThis study compares two surgical approaches for women with middle-to-high risk endometrial cancer that hasn't spread beyond the uterus. One group gets sentinel lymph node sampling (removing only a few key nodes), while the other gets standard pelvic lymphadenectomy (removing many…
Phase: NA • Sponsor: Xiaojun Chen • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Scientists reprogram immune cells to attack common cancer mutation
Disease control OngoingThis early-stage trial tests a personalized treatment for people with metastatic solid cancers that have KRAS mutations. Doctors take a patient's own white blood cells, genetically modify them to recognize and attack KRAS-mutated cancer cells, and return them to the patient along…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy for endometrial cancer shows promise in early trial
Disease control OngoingThis early-phase trial is testing whether adding the immunotherapy drug pembrolizumab to standard radiation and chemotherapy is safe and feasible for people with high-intermediate risk endometrial cancer. About 45 participants who have already had surgery to remove the uterus wil…
Phase: PHASE1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug ZW191 targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…
Phase: PHASE1 • Sponsor: Zymeworks BC Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug XmAb20717 tested in rare cancers – trial suspended
Disease control TerminatedThis phase II trial tests the safety and effectiveness of a drug called XmAb20717 in 140 people with advanced rare cancers, including mesothelioma, lymphoma, and small cell lung cancer. The drug is given by IV. The main goal is to see if tumors shrink. The trial is currently susp…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Immunotherapy shows promise in battle against aggressive uterine cancer
Disease control OngoingThis Phase 3 trial compares the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy in 280 women with advanced or recurrent endometrial cancer that has a specific genetic feature (dMMR). The goal is to see if pembrolizumab can better delay cancer growth and impro…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy shows promise for Hard-to-Treat vulvar cancer
Disease control OngoingThis study tests whether combining standard chemotherapy (cisplatin) and radiation with an immunotherapy drug (pembrolizumab) can shrink or control advanced vulvar cancer that cannot be removed by surgery. The trial includes 24 adults with unresectable, recurrent, or metastatic v…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New gene therapy combo shows promise in ovarian cancer trial
Disease control OngoingThis study tests whether adding a gene therapy called IMNN-001 to standard chemotherapy can help people with advanced ovarian, fallopian tube, or peritoneal cancer live longer without their cancer growing. About 130 newly diagnosed patients will receive either the combination or …
Phase: PHASE1, PHASE2 • Sponsor: Imunon • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Virus therapy takes on Platinum-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new approach for ovarian cancer that has stopped responding to platinum chemotherapy. It combines TILT-123, a virus engineered to kill cancer cells and boost immune activity, with the immunotherapy drug pembrolizumab, and in some cases also with a c…
Phase: PHASE1, PHASE2 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pfizer drug shows promise against tough cancers
Disease control OngoingThis study tests a new drug called PF-07104091 in people with advanced small cell lung cancer, ovarian cancer, or certain breast cancers that have not responded to prior treatments. The goal is to find the safest dose and see if the drug shrinks tumors, either alone or with other…
Phase: PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug cocktail shows promise for rare sarcomas
Disease control OngoingThis phase II trial tests whether combining cabozantinib (a targeted therapy) with temozolomide (a chemotherapy drug) can slow tumor growth in people with advanced leiomyosarcoma or other soft tissue sarcomas that cannot be surgically removed or have spread. About 96 participants…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Immunotherapy before surgery shows promise for aggressive uterine cancer
Disease control OngoingThis study tests whether giving the immunotherapy drug pembrolizumab before standard surgery can shrink tumors in people with a specific type of uterine cancer (MMRd). Twelve participants will receive 9 cycles of pembrolizumab before their hysterectomy. The goal is to see how man…
Phase: PHASE2 • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Can a vaginal probiotic stick around? new study follows women who got the treatment
Disease control ENROLLING_BY_INVITATIONThis study is for women who previously received a vaginal probiotic (LC106) for bacterial vaginosis in an earlier trial. Researchers want to see if the good bacteria from the probiotic can stay in the vagina over time. About 71 women will be followed, and the main goal is to chec…
Phase: EARLY_PHASE1 • Sponsor: Caroline Mitchell • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New antibody drug takes on advanced cancers in first human trial
Disease control OngoingThis early-phase trial is testing a new drug called NTX-1088, which targets a protein on cancer cells, either alone or combined with the immunotherapy pembrolizumab. The study involves 90 people with advanced solid tumors that have spread or cannot be removed. The main goals are …
Phase: PHASE1 • Sponsor: Nectin Therapeutics Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Two-Drug combo shows promise for Hard-to-Treat uterine cancer
Disease control OngoingThis phase II study tests whether the combination of letrozole (Femara) and everolimus (Afinitor) can help control advanced or recurrent endometrial cancer. The trial enrolled 42 participants whose cancer had progressed or returned. Researchers are measuring how many patients res…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental cell therapy for advanced gynecological cancers halted before start
Disease control TerminatedThis study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Can a Nurse-Led program transform Women's health in hong kong?
Disease control OngoingThis trial tests a nurse-led health program for women aged 45 to 64 in Hong Kong. The program uses a 5-step approach (ask, advice, assess, assist, arrange) to help women manage conditions like high blood pressure, anxiety, and menopause symptoms. Researchers will compare the prog…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Promising drug shrinks tumors in advanced cancers
Disease control OngoingThis study tested a drug called sacituzumab govitecan in 227 people whose solid tumors had spread to other parts of the body. The main goal was to see if the drug could shrink tumors. Researchers measured how many patients had their tumors shrink or disappear. This is not a cure,…
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New drug combo shows promise in battling recurrent ovarian cancer
Disease control OngoingThis study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Could a sleep hormone help unborn babies grow?
Disease control ENROLLING_BY_INVITATIONThis study tests whether giving melatonin to pregnant women with a severe form of fetal growth restriction can help their babies. The trial will involve 240 women who will take either melatonin or a placebo nightly. Researchers will track baby growth, pregnancy length, and newbor…
Phase: PHASE1 • Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can stem cells restore fertility in early menopause?
Disease control TerminatedThis study tests whether stem cells from umbilical cords can safely help women with premature ovarian failure (early menopause). Twelve participants receive stem cell infusions, and doctors monitor menstrual cycles, hormone levels, and follicle growth. The goal is to see if this …
Phase: PHASE2 • Sponsor: Sclnow Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Simple surgical tweak may cut prolapse return rate
Disease control OngoingThis study tests whether adding a posterior repair (tightening the vaginal opening) to standard prolapse surgery helps prevent the prolapse from returning within a year. About 200 women with advanced prolapse are taking part. Half get the extra procedure, half do not, and researc…
Phase: NA • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
MRI-Guided radiation: a sharper weapon against gynecologic cancer?
Disease control OngoingThis study tests new MRI-based tools to make brachytherapy—a type of internal radiation—more accurate for gynecologic cancer. Researchers will compare standard brachytherapy with an MRI-guided version in 49 patients to see if it improves radiation delivery. The goal is better tum…
Phase: NA • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can a 48-Hour drug delay help babies after water breaks early?
Disease control OngoingThis study tests whether giving nifedipine, a drug that relaxes the uterus, for 48 hours can improve health outcomes for babies when a pregnant person's water breaks too early (between 22 and 34 weeks). About 857 participants will receive either nifedipine or a placebo. The goal …
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Cancer drug combo trial pulled before it even started
Disease control TerminatedThis study was designed to test the safety and effectiveness of two drugs, bemarituzumab and bevacizumab, given together to people with advanced gynecologic cancers (endometrial, ovarian, or cervical) that have a specific protein called FGFR2b. The trial was withdrawn before enro…
Phase: PHASE1, PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail shows promise against Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called ceralasertib, alone or with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, and endometrial cancers. The goal is to see if these combinations can shrink tumors by blocking enzymes that help cancer grow.…
Phase: PHASE2 • Sponsor: Rahul Aggarwal • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could stem cells help women with thin uterine lining get pregnant?
Disease control TerminatedThis early-stage study tests whether stem cells from umbilical cords can help women with a thin uterine lining become pregnant. The treatment aims to thicken the lining and reduce scarring, potentially improving pregnancy and live birth rates. The study involves 24 women aged 20-…
Phase: PHASE1 • Sponsor: Sclnow Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Can freezing ovarian tissue help girls have babies later?
Disease control OngoingThis study offers girls from birth to age 17 the chance to freeze their ovarian tissue before medical treatments that could harm their fertility, such as chemotherapy or radiation. The tissue is removed surgically and stored. Later, if they want to have children, the tissue can b…
Phase: NA • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug cocktail shows promise for tough cancers
Disease control OngoingThis study is testing a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and bevacizumab (a drug that blocks blood vessel growth)—in people with advanced solid tumors, including ovarian, breast, lung, and gastric cancers. The goal is to see…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new oral drug called MOMA-313, alone or with another drug (olaparib), in people with advanced solid tumors that have certain DNA repair flaws. The main goals are to check safety and find the right dose. About 220 adults with cancers like prostate, p…
Phase: PHASE1 • Sponsor: MOMA Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Weight loss program aims to cut cancer risk in BRCA and lynch syndrome carriers
Disease control OngoingThis study tests a weight management and health behavior program for people with BRCA or Lynch syndrome mutations, who have a higher risk of certain cancers. Participants receive diet tracking, exercise guidance, phone coaching, and online support to help them lose weight and ado…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo aims to control Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, selumetinib and olaparib, in people with advanced or recurrent solid tumors (including ovarian, endometrial, breast, and others) that have specific genetic changes or have stopped responding to similar treatments. The first phase finds…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Could a bone drug help fight ovarian cancer?
Disease control OngoingThis pilot study tests whether adding zoledronic acid (a bone-strengthening drug) to standard chemotherapy and a targeted therapy can help women with ovarian cancer that no longer responds to platinum-based treatment. The study involves 14 participants and focuses on measuring im…
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
MRI-Guided radiation: a sharper aim for HPV cancers?
Disease control OngoingThis early-phase trial tests whether using MRI scans to guide the placement of internal radiation (brachytherapy) can improve treatment for women with advanced cervical or vaginal cancers linked to HPV. The study involves 26 participants and compares MRI-guided placement to stand…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Vaccine boosts Chemo-Radiation against cervical cancer in early trial
Disease control OngoingThis phase 2 trial tests whether adding a vaccine called PDS0101 to standard chemoradiation is safe and effective for people with advanced cervical cancer. The vaccine trains the immune system to attack HPV-infected tumor cells. About 22 participants will receive the combination,…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for endometrial cancer: drug combo shows promise
Disease control OngoingThis study tests a combination of drugs (durvalumab, chemotherapy, and olaparib) as a first treatment for people with advanced or recurrent endometrial cancer that has a specific genetic marker (pMMR). The goal is to see how safe and tolerable the treatment is. About 85 people in…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Bacteria bombs target stubborn tumors in new cancer combo trial
Disease control OngoingThis study tests a special bacteria (Clostridium novyi-NT) injected directly into tumors, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors that haven't responded to standard treatments. The bacteria are designed to break down tumor cells f…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo shows promise for tough ovarian cancers
Disease control OngoingThis study tests whether adding an experimental drug (AZD1775) to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 women will be randomly assigned to receive eith…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could chemo after surgery beat endometrial cancer relapse?
Disease control OngoingThis study looks at whether giving chemotherapy after surgery can help people with early-stage (stage I-II) endometrial cancer who have a higher risk of the cancer coming back. About 244 patients will either receive six cycles of carboplatin and paclitaxel or simply be observed. …
Phase: PHASE2 • Sponsor: Danish Gynecological Cancer Group • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for hard-to-treat ovarian cancer: drug duo enters phase 2 trial
Disease control OngoingThis study tests whether combining two immunotherapy drugs, ONC-392 and pembrolizumab, can shrink tumors in people with platinum-resistant ovarian cancer. About 58 adults with high-grade serous ovarian, primary peritoneal, or fallopian tube cancer are taking part. The goal is to …
Phase: PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New pill could shrink uterine cancer without surgery
Disease control OngoingThis phase II trial is testing an oral drug called giredestrant in 30 people with grade 1 endometrial cancer. The goal is to see if the drug can shrink or control the cancer over 6 months. Participants take one pill daily for up to 24 cycles, and doctors monitor tumor changes and…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug shows promise against multiple Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New combo immunotherapy drug enters human trials for 18 cancers
Disease control OngoingThis early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…
Phase: PHASE1 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Heated chemo during surgery may boost ovarian cancer survival
Disease control OngoingThis study tests whether adding heated chemotherapy directly into the abdomen during surgery helps people with stage III ovarian cancer live longer. About 538 participants will be randomly assigned to standard surgery alone or surgery plus the heated chemo. The main goal is to se…
Phase: PHASE3 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New antibody combo shows promise in early cancer trial
Disease control OngoingThis trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Genetically modified immune cells take on eight cancer types in early trial
Disease control OngoingThis early-stage trial tests a personalized cell therapy called ADP-A2M4CD8 in people with certain cancers that have a specific marker (MAGE-A4). The therapy uses a patient's own immune cells, modified to better attack tumors, and is given alone or with standard immunotherapy dru…
Phase: PHASE1 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Engineered immune cells target Hard-to-Treat ovarian cancer
Disease control OngoingThis early-phase trial tests a new approach for people with ovarian, fallopian tube, or peritoneal cancer that has returned or not responded to standard treatments. Patients receive their own T cells, which are genetically modified to recognize and attack cancer cells, along with…
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New antibody combo shows promise for tough ovarian cancer
Disease control OngoingThis trial tests a new drug combination for women with recurrent ovarian cancer that has come back after initial treatment. The study includes 54 participants and uses an antibody called oregovomab along with standard chemotherapy and bevacizumab. The goal is to see if this mix i…
Phase: PHASE1, PHASE2 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Stem cell shot into ovaries aims to tame perimenopause symptoms
Disease control ENROLLING_BY_INVITATIONThis study looks at whether injecting special stem-like cells called Muse cells directly into the ovaries can help women aged 28 to 70 who are in perimenopause. The cells may repair tissue, reduce inflammation, and improve hormone balance. Researchers will track safety, hormone l…
Sponsor: Healing Hope International • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could stem cell exosomes restore fertility? new trial tests hope for early ovarian failure
Disease control OngoingThis early-stage study tests whether exosomes from umbilical cord stem cells can help women with premature ovarian insufficiency (early menopause). The treatment aims to improve ovarian function and quality of life. About 60 women aged 20-39 will receive the experimental therapy,…
Phase: PHASE1, PHASE2 • Sponsor: International Peace Maternity and Child Health Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental cell therapy targets Hard-to-Treat ovarian cancers
Disease control OngoingThis early-phase trial tests a new immune cell therapy called FT536 for people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. The treatment is given directly into the abdomen after a short course of chemotherapy. Only 3 participants are enrolled, so the mai…
Phase: PHASE1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for endometrial cancer: targeted drug takes on chemo in major trial
Disease control OngoingThis study tests a new drug, MK-2870, against standard chemotherapy in about 710 people with endometrial cancer that has worsened after platinum chemo and immunotherapy. The goal is to see if MK-2870 helps people live longer and delays cancer growth. Participants are randomly ass…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Could an arthritis drug boost IVF success in endometriosis patients?
Disease control OngoingThis study tests whether giving an anti-inflammatory drug (anti-TNFα) a few days before a frozen embryo transfer can help women with endometriosis who have had a failed IVF cycle get pregnant. The trial involves 145 participants and compares the clinical pregnancy rate to standar…
Phase: PHASE2 • Sponsor: Benha University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Immunotherapy combo shows promise against rare, tough ovarian cancer
Disease control OngoingThis study tests whether a combination of two immune-boosting drugs (nivolumab and ipilimumab) works better than nivolumab alone for people with advanced clear cell cancers of the ovary, fallopian tube, peritoneum, or other areas. About 46 participants will receive one of the two…
Phase: PHASE2 • Sponsor: Brown University • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Ovarian cancer drug study pulled before it even started
Disease control TerminatedThis study aimed to test new cancer drugs, alone or in combination, for people with advanced or recurrent ovarian cancer. The treatments were chosen based on specific genetic markers in each person's tumor. However, the study was withdrawn before enrolling any participants, so no…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug duo aims to stall ovarian Cancer's return
Disease control OngoingThis phase 2 trial is testing whether adding oregovomab (an antibody) to niraparib (a daily pill) can better control platinum-sensitive recurrent ovarian cancer. Ten women whose cancer came back after initial chemotherapy will receive both drugs for 12 weeks. The main goal is to …
Phase: PHASE2 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Keytruda takes on genetic weak spots in advanced tumors
Disease control OngoingThis phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New Two-Drug immune attack launched against tough cancers
Disease control OngoingThis early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…
Phase: PHASE1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug cocktail shows promise for recurrent ovarian cancer
Disease control OngoingThis study tested a combination of three drugs—nivolumab, bevacizumab, and rucaparib—in 72 people whose ovarian, fallopian tube, or peritoneal cancer had returned after standard treatment. The goal was to see if the drugs could shrink tumors or slow the cancer's growth. While som…
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Experimental antibody boosts chemo in ovarian cancer trial
Disease control OngoingThis phase 2 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps control advanced ovarian, fallopian tube, or peritoneal cancer better than chemo alone. About 88 women with newly diagnosed stage III or …
Phase: PHASE2 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Ovarian cancer hope: new antibody combo aims to delay disease worsening
Disease control OngoingThis Phase 3 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps people with newly diagnosed advanced ovarian cancer live longer without their cancer getting worse. About 615 participants who had surger…
Phase: PHASE3 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Text and phone support helps cervical cancer survivors kick the habit
Disease control OngoingThis study tests whether a program combining phone counseling and personalized text messages can help 360 cervical cancer survivors in Florida quit smoking better than standard quitline services. Participants must have a history of cervical cancer or high-grade cervical dysplasia…
Phase: NA • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New combo therapy shows promise for Hard-to-Treat cervical cancer
Disease control OngoingThis study tests whether adding targeted radiation (SBRT) to the immunotherapy drug atezolizumab can shrink tumors better than atezolizumab alone in people with cervical cancer that has come back or spread. About 21 adults with advanced cervical cancer are participating. The goal…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for rare cancers? drug combo shows promise in early trial
Disease control OngoingThis phase 2 study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare tumors that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. Participants take one of the two drugs, and researchers measure how long the cancer…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug combo shows promise for rare uterine cancer in early trial
Disease control OngoingThis phase II trial is testing whether combining niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy) can shrink or control recurrent or persistent uterine serous carcinoma. The study enrolled 8 women whose cancer had returned after standard chemotherapy. Researchers a…
Phase: PHASE2 • Sponsor: Casey Cosgrove • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for rare ovarian cancer: could hormone therapy replace chemo?
Disease control OngoingThis study tests whether the hormone therapy letrozole alone works as well as chemotherapy (paclitaxel and carboplatin) followed by letrozole for people with stage II-IV low-grade serous ovarian, fallopian tube, or peritoneal cancer. About 450 participants will be randomly assign…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called E7386 combined with other cancer drugs in people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find the safest and most effective dose and to see if the combination can shrink tumors. About 300 …
Phase: PHASE1, PHASE2 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Womb transplants could let infertile women give birth
Disease control OngoingThis study is testing whether a uterus transplant from a living or deceased donor can help women who were born without a uterus or had it removed to have a baby. Up to 38 women with working ovaries will receive a transplant and then try to get pregnant through IVF. The main goal …
Phase: NA • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Green tea extract may boost fertility in women with fibroids
Disease control OngoingThis study tests whether a low-caffeine green tea extract (EGCG) can shrink uterine fibroids and improve pregnancy and live birth rates in women aged 18-40 who have been trying to conceive for at least six months. Participants take the extract and are monitored for changes in fib…
Phase: PHASE3 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Bagged and fragmented: a Scar-Free way to remove large uteri?
Disease control OngoingThis study tests a new surgical technique to remove large uteri through the vagina using a sealed bag and electric fragmentation. The goal is to avoid abdominal scars and prevent the spread of tissue fragments. Twenty-five women aged 38 to 52 with large uteri are participating. T…
Sponsor: Chang Zhou • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New stitching tool aims to fix pelvic organ prolapse
Disease control ENROLLING_BY_INVITATIONThis study tests a new device called i-Stitch for repairing pelvic organ prolapse in 100 women. The device is used to attach the top of the vagina to a ligament in the pelvis. The goal is to see if it is safe and works well. Researchers will measure symptoms, quality of life, and…
Sponsor: A.M.I. Agency for Medical Innovations GmbH • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New device aims to prevent vaginal scarring after cancer radiation
Disease control ENROLLING_BY_INVITATIONThis study tests a special device that combines a vaginal dilator with a drug delivery tube to help prevent vaginal narrowing and scarring after pelvic radiation therapy. About 76 women aged 18-70 who have completed radiation for pelvic tumors will use the device regularly. The g…
Phase: NA • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Heated chemotherapy during surgery may delay ovarian cancer return
Disease control OngoingThis phase 3 trial tests whether giving heated chemotherapy directly into the abdomen during surgery can help people with advanced ovarian cancer live longer without the disease coming back. About 362 participants will either receive standard surgery alone or surgery plus the hea…
Phase: PHASE3 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New texting system aims to boost cervical cancer screening in kenya
Disease control OngoingThis study tests a web-based tool called the Cancer Tracking System (CATSystem) that sends automated texts and alerts to help women in Kenya get timely cervical cancer screening and follow-up care. About 6,600 women across 10 hospitals will take part, with half the hospitals usin…
Phase: NA • Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New surgical bag aims to keep fibroids contained during keyhole surgery
Disease control OngoingThis study tests a fully enclosed protective bag used during laparoscopic myomectomy to remove uterine fibroids. The bag is meant to keep fibroid tissue completely isolated, preventing any leakage or spread during the procedure. Twenty women aged 28-46 with fibroids 6-10 cm will …
Sponsor: China-Japan Friendship Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug may delay return of ovarian cancer
Disease control OngoingThis study tests a drug called BGB-290 (Pamiparib) as a maintenance treatment for people with recurrent ovarian cancer whose tumors shrank or disappeared after platinum-based chemotherapy. The goal is to see if taking this drug daily can delay the cancer from coming back. The tri…
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for rare cancers: drug duo shows promise
Disease control OngoingThis phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New combo aims to outsmart Platinum-Resistant ovarian cancer
Disease control OngoingThis study tests a new drug called NP-G2-044 (Prilukae) combined with standard chemotherapy (PLD) in people with ovarian cancer that no longer responds to platinum-based treatments. About 380 participants will receive either the combo or PLD alone to see if the combination improv…
Phase: PHASE2, PHASE3 • Sponsor: Novita Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo shows promise for Tough-to-Treat uterine cancer
Disease control OngoingThis study tests a combination of two drugs, cadonilimab and lenvatinib, in 32 people with advanced endometrial cancer that has spread or come back and no longer responds to standard chemotherapy. The goal is to see if the combination shrinks tumors and how long it keeps the canc…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug duo aims to halt endometrial cancer growth
Disease control OngoingThis study tests a combination of two drugs, abemaciclib and letrozole, in people with advanced or recurrent endometrioid endometrial cancer that cannot be cured by surgery or radiation. The main goal is to see how many participants have no cancer growth after 6 months of treatme…
Phase: PHASE2 • Sponsor: Gynecologic Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…
Phase: PHASE1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Ovarian cancer trial hopes immunotherapy can buy more time
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel, with or without bevacizumab) can slow the growth of ovarian cancer that has become resistant to platinum-based treatments. About 643 adults with recurrent ovarian, fallopian…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New pill may keep ovarian cancer at bay after chemo
Disease control OngoingThis study tests whether a daily pill called niraparib can help keep advanced ovarian cancer from coming back after initial chemotherapy. About 733 women with stage III or IV ovarian cancer who responded to platinum-based chemo took either niraparib or a placebo. The main goal wa…
Phase: PHASE3 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for cervical cancer: drug combo targets tumors resistant to immunotherapy
Disease control OngoingThis phase 2 trial tests a combination of two drugs—zimberelimab (an immunotherapy) and lenvatinib (a targeted therapy)—in 30 patients with advanced cervical cancer that has worsened after prior immunotherapy. The goal is to see if the combo can shrink tumors or slow disease prog…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Heated chemo during surgery may fight ovarian cancer return
Disease control OngoingThis early-phase trial tests whether giving heated chemotherapy directly into the abdomen during surgery can help prevent cancer from coming back in people with advanced ovarian, fallopian tube, uterine, or peritoneal cancer. About 40 participants will receive the heated chemo du…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New hope for hard-to-treat ovarian cancer: targeted drug shows promise in early trial
Disease control OngoingThis study tests a drug called sacituzumab govitecan in 20 people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The drug works like a guided missile, delivering chemotherapy directly to cancer cells. The mai…
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug combo shows promise for rare ovarian cancer
Disease control OngoingThis pilot phase II study tests whether the drugs fulvestrant and abemaciclib can help control low-grade serous ovarian cancer in women with advanced disease. Up to 18 participants will receive the drugs before and after surgery. The goal is to see how many patients achieve a par…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New triple therapy targets hard-to-treat ovarian cancer
Disease control OngoingThis study tests a combination of three drugs—ALX148, liposomal doxorubicin, and pembrolizumab—in people with recurrent ovarian cancer that no longer responds to platinum-based chemotherapy. The goal is to see if blocking the CD47 protein on cancer cells can boost the immune syst…
Phase: PHASE2 • Sponsor: Alexander B Olawaiye, MD • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug combo shows promise for Hard-to-Treat uterine cancer
Disease control OngoingThis study tests a combination of two drugs, alpelisib and fulvestrant, in people with a specific type of advanced uterine cancer (endometrioid endometrial cancer) that has a PIK3CA gene mutation. The goal is to see if the treatment can shrink or control the cancer. About 51 part…
Phase: PHASE2 • Sponsor: GOG Foundation • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for ovarian cancer: drug may delay return of disease
Disease control OngoingThis study tests whether the drug olaparib can help keep advanced ovarian cancer from coming back in people who do not have a BRCA gene mutation. Participants have already responded well to initial chemotherapy. The trial compares olaparib to a placebo to see if it extends the ti…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug combo shows promise for rare, aggressive uterine cancer
Disease control OngoingThis study tests whether combining two drugs, pembrolizumab and lenvatinib, can shrink tumors or slow cancer growth in people with advanced uterine or ovarian carcinosarcoma, a rare and aggressive cancer. About 40 participants will receive the treatment, and researchers will also…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New combo therapy aims to delay ovarian cancer return
Disease control OngoingThis phase 2 trial tests whether a combination of three drugs—olaparib, durvalumab, and a cancer vaccine called UV1—can help keep ovarian cancer from coming back after chemotherapy. The study includes 188 patients with recurrent ovarian cancer who do not have BRCA mutations. Part…
Phase: PHASE2 • Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New hope for rare cervical cancer: drug trial targets tumor control
Disease control OngoingThis study tests a drug called AK104 (Cadonilimab) in 18 adults with a rare, aggressive cervical cancer that has returned or spread after standard chemotherapy. The goal is to see if the drug can stop the cancer from growing for at least 6 months. Participants receive the drug al…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Immunotherapy duo takes on rare cancers
Disease control OngoingThis Phase 2 trial is testing whether combining two immunotherapy drugs, ipilimumab and nivolumab, can shrink or control rare cancers that are known to respond to immunotherapy. The study includes 240 people with advanced biliary tract, neuroendocrine, gynecologic, or MSI-H solid…
Phase: PHASE2 • Sponsor: Olivia Newton-John Cancer Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New cell therapy takes on recurrent ovarian cancer
Disease control OngoingThis study tests a new treatment called ADP-A2M4CD8, made from a patient's own immune cells, for ovarian cancer that has returned. It is given alone or with another drug (nivolumab) to see if it can shrink tumors. About 66 people with a specific genetic marker (HLA-A*02 and MAGE-…
Phase: PHASE2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New PET tracer could spot cancers that standard scans overlook
Diagnosis OngoingThis phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jul 04, 2026 00:00 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
New study aims to improve cervical cancer detection in HIV-Positive women
Diagnosis OngoingThis study compares different HPV tests to find the best way to screen for cervical cancer in women living with HIV in Latin America. Over 1,000 participants will provide cervical, vaginal, and urine samples, plus undergo colposcopy and biopsies. The goal is to identify which tes…
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
AI could help ultrasound spot ovarian cancer earlier
Diagnosis OngoingThis study is testing whether artificial intelligence can help ultrasound scans better detect ovarian cancer in postmenopausal women. About 100 women with certain types of ovarian cysts will have their ultrasound images analyzed by AI. The goal is to see if the AI can match or be…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
Could a simple Self-Swap replace the speculum for cervical cancer screening?
Diagnosis OngoingThis study compares self-collected vaginal samples to clinician-collected samples for HPV testing in 500 people referred for colposcopy. The goal is to see if self-collection is accurate enough to improve cervical cancer screening rates. Participants will provide both types of sa…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Could a DIY swab replace the pelvic exam for cervical cancer screening?
Diagnosis OngoingThis study tests whether women can collect their own vaginal samples for HPV testing as accurately as a doctor's sample. It involves 750 women referred for colposcopy or cervical procedures. The goal is to see if self-collection is a reliable alternative to traditional pelvic exa…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Ovarian cancer recurrence detection study pulled before starting
Diagnosis TerminatedThis study was designed to see if a blood test called the ROMA score could find ovarian cancer coming back sooner than the usual CA125 test. The goal was to catch recurrences early, which might allow less invasive surgery and improve quality of life. However, the study was withdr…
Phase: NA • Sponsor: University Hospital, Tours • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
New ultrasound technique could end the need for surgery to diagnose endometriosis
Diagnosis ENROLLING_BY_INVITATIONThis study tests a new ultrasound technique called SonoPODography (SPG) to diagnose superficial endometriosis, the most common form of the disease. Currently, diagnosis requires invasive surgery. The procedure involves injecting saline into the pelvis to create a clearer view of …
Sponsor: McMaster University • Aim: Diagnosis
Last updated Jun 27, 2026 13:04 UTC
-
Period blood may hold key to endometriosis diagnosis
Diagnosis ENROLLING_BY_INVITATIONThis study looks at whether a simple menstrual blood sample can help predict endometriosis in women aged 18-40 with symptoms like pelvic pain. Researchers will analyze cells in the blood to find patterns linked to the disease. The goal is to create a test that helps decide if sur…
Sponsor: Northwell Health • Aim: Diagnosis
Last updated Jun 27, 2026 13:02 UTC
-
New scan could sharpen cervical cancer staging
Diagnosis OngoingThis study tests whether a combined PET/MRI scan can more accurately show how deep cervical cancer has grown and whether it has spread to lymph nodes. About 25 people with early-stage cervical cancer that can be removed by surgery will get the scan before their operation. The goa…
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:35 UTC
-
Could a DIY swab replace the speculum for cervical cancer screening?
Diagnosis OngoingThis study compares HPV testing on self-collected vaginal samples versus samples collected by a doctor during a pelvic exam. About 500 people referred for colposcopy or cervical procedures will provide both types of samples. The goal is to see if self-collection is accurate enoug…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
New scan and dye combo may spot hidden cancer in lymph nodes
Diagnosis OngoingThis study looks at whether combining a special scan (PET/CT) with a dye that highlights lymph nodes can better detect cancer spread in women with high-risk endometrial cancer. About 100 women scheduled for surgery will get both tests before their operation. The goal is to see if…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
New study aims to improve cervical cancer screening for women in botswana
Diagnosis OngoingThis study evaluates different cervical cancer screening methods using HPV testing in Botswana, involving 3000 women aged 25 and older. Researchers compare HPV genotype restriction with visual inspection to find the most accurate way to detect high-grade cervical dysplasia. The g…
Phase: NA • Sponsor: Beth Israel Deaconess Medical Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:24 UTC
-
New scan may better spot ovarian cancer tumors before surgery
Diagnosis OngoingThis study compares two types of imaging scans—PET/MR and contrast-enhanced CT (CECT)—to see which one better locates ovarian cancer tumors in the abdomen. Researchers aim to find out if PET/MR can more accurately predict whether tumors can be fully removed during surgery and how…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:08 UTC
-
New MRI technique could sharpen views of gynecologic tumors
Diagnosis OngoingThis study tests a new type of DCE-MRI that takes pictures faster and reduces blurring from movement. The goal is to see if it gives clearer images of gynecologic tumors than traditional MRI. About 24 women with gynecologic cancer and healthy volunteers will take part. The new sc…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 12:03 UTC
-
Spit test could spot ovarian cancer earlier
Diagnosis OngoingThis study looks at whether RNA in saliva can help tell the difference between ovarian cancer, borderline tumors, and benign cysts. Researchers are collecting saliva samples from 746 women before and after surgery. The goal is to find a simple, non-invasive way to speed up diagno…
Sponsor: ZIWIG • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
New saliva test aims to simplify endometriosis diagnosis
Diagnosis TerminatedThis study was designed to check how well a new saliva test, called Endotest®, can diagnose endometriosis. Researchers planned to test the test's repeatability, how time of day affects results, and sample stability. The study was withdrawn before enrolling any participants, so no…
Phase: NA • Sponsor: ZIWIG • Aim: Diagnosis
Last updated Jun 27, 2026 12:01 UTC
-
Saliva test may spare women from unnecessary surgery for endometriosis
Diagnosis OngoingThis study looks at whether a simple saliva test (Ziwig Endotest) can help doctors make better decisions about managing endometriosis in women with chronic pelvic pain but unclear imaging results. Over 2,500 women will provide a saliva sample, and researchers will compare treatme…
Phase: NA • Sponsor: ZIWIG • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
Can a simple HPV test replace colposcopy for cervical cancer Follow-Up?
Diagnosis OngoingThis study compares two ways to check for returning cervical pre-cancer after treatment: the standard colposcopy exam versus a high-risk HPV DNA test. Over 2,200 women who were treated for high-grade cervical lesions will be randomly assigned to one of the two follow-up methods. …
Phase: NA • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Diagnosis
Last updated Jun 27, 2026 11:03 UTC
-
New scan may spot endometriosis without surgery
Diagnosis ENROLLING_BY_INVITATIONThis study tests whether a special PET/MRI scan can find endometriosis more accurately than current methods like ultrasound or MRI alone. About 60 women with suspected endometriosis will get the scan before surgery, and results will be compared to surgical findings. If successful…
Sponsor: Massachusetts General Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 11:01 UTC
-
Cervical cancer screening showdown: pap vs. blood test study pulled
Diagnosis TerminatedThis study was designed to compare the standard Pap smear with a new blood test that looks for three proteins linked to cervical cell changes. It planned to include adults aged 18-85 in good health. However, the study was withdrawn before enrolling any participants, so no results…
Phase: NA • Sponsor: Timser SAPI de CV • Aim: Diagnosis
Last updated Jun 27, 2026 09:09 UTC
-
One shot to stop cancer: HPV vaccine study could change global prevention
Prevention OngoingThis study tests whether a single dose of the HPV vaccine can protect young women aged 18-30 from cervical cancer. Researchers in Costa Rica are giving 5,000 women either one HPV shot or a placebo to see if one dose is enough to prevent persistent HPV infections that can lead to …
Phase: PHASE4 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jul 02, 2026 00:00 UTC
-
Can reminders and education prevent cervical cancer? a new trial aims to find out.
Prevention OngoingThis trial tests whether a program that combines educational materials with electronic health record reminders can increase HPV vaccination rates among children and young adults aged 11–26 in four Appalachian states. The goal is to improve vaccine uptake and ultimately prevent ce…
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Could a simple addition to gallbladder surgery help prevent ovarian cancer?
Prevention OngoingThis study tests whether removing the fallopian tubes during planned gallbladder removal surgery is safe for women aged 45 and older. The goal is to see if this extra step can help prevent ovarian cancer without causing more complications. About 300 women will take part, with hal…
Phase: NA • Sponsor: University of Zurich • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
At-Home style HPV test at Walk-In clinics could boost cancer screening
Prevention ENROLLING_BY_INVITATIONThis study tests whether offering women a simple self-collection kit for HPV testing at Express Care clinics (which have evening and weekend hours) increases cervical cancer screening rates. About 500 women aged 30–63 who are overdue for screening will either receive usual care o…
Phase: NA • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC
-
Smart supplement strategy could save babies in ethiopia
Prevention OngoingThis study in Addis Ababa, Ethiopia, tests whether giving protein supplements only to pregnant women who are undernourished can prevent problems like low birth weight and stillbirth. Over 6,700 pregnant women are randomly assigned to receive supplements either universally or only…
Phase: NA • Sponsor: Harvard School of Public Health (HSPH) • Aim: Prevention
Last updated Jun 27, 2026 12:34 UTC
-
Two eggs a day for healthier babies? new study tests simple fix for malnutrition
Prevention OngoingThis study tests whether pregnant women who eat two eggs daily have babies with longer birth lengths and better development. Researchers in Rwanda are giving eggs to some women and comparing them to those eating their usual diet. The goal is to see if this simple, affordable food…
Phase: NA • Sponsor: University of Florida • Aim: Prevention
Last updated Jun 27, 2026 12:30 UTC
-
Quick therapy after rape may stop PTSD before it starts
Prevention OngoingThis study tests whether a short, modified exposure therapy given soon after rape can prevent post-traumatic stress disorder (PTSD) in women. About 166 women who have experienced sexual assault will be randomly assigned to either the brief therapy or standard care. The goal is to…
Phase: NA • Sponsor: St. Olavs Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:30 UTC
-
At-Home cervical cancer screening could save lives in rural uganda
Prevention OngoingThis study looks at whether women in rural Uganda can screen themselves for cervical cancer using a simple HPV test at home. Over 2,500 women aged 25-49 will collect their own samples during community health campaigns. The goal is to see if this approach increases screening rates…
Sponsor: University of California, San Francisco • Aim: Prevention
Last updated Jun 27, 2026 12:28 UTC
-
Could a simple HPV test every 5 years replace frequent pap smears?
Prevention OngoingThis study compares two ways to screen for cervical cancer: a Pap smear every 2.5 years versus an HPV test every 5 years. Over 76,000 women aged 25-69 in Australia are taking part, including those who received the HPV vaccine and those who did not. The goal is to see if the less …
Phase: NA • Sponsor: VCS Foundation • Aim: Prevention
Last updated Jun 27, 2026 12:09 UTC
-
New study tests two-step surgery to delay menopause while cutting ovarian cancer risk
Prevention OngoingThis study looks at three approaches to prevent ovarian cancer in women with BRCA1 or BRCA2 gene mutations: regular screening, removing both fallopian tubes and ovaries at once, or removing only the fallopian tubes first and the ovaries later. The two-step surgery aims to delay m…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 12:07 UTC
-
Can diet and exercise programs cut cancer risk? new study tests lifestyle changes
Prevention OngoingThis study tests different programs to help people at high risk for cancer (such as those with BRCA or Lynch syndrome) or cancer survivors increase their physical activity and eat healthier. The goal is to see which programs work best to reduce cancer risk. About 337 participants…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 11:00 UTC
-
Could a High-Tech headband clear the fog of chemo brain?
Symptom relief TerminatedThis study tests whether a headband with special semiconductors can help with memory and thinking problems (often called 'chemo brain') in people who have had breast or gynecologic cancer. About 50 participants will wear either the active headband or a placebo version for 18 hour…
Phase: PHASE2 • Sponsor: University of Utah • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Can virtual reality help women overcome vaginismus?
Symptom relief OngoingThis study is testing whether virtual reality exposure therapy can help people with vaginismus, a condition where the pelvic floor muscles tighten involuntarily, making vaginal penetration painful or impossible. The idea is that gradually facing feared situations in a safe virtua…
Phase: NA • Sponsor: University of British Columbia • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Ear seeds may boost IVF success by calming anxiety
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a simple ear acupressure technique, called auricular point sticking therapy, can reduce anxiety and improve sleep in women undergoing IVF. 178 women aged 20-45 with anxiety or insomnia will either receive standard IVF care or standard care plus ear acupre…
Phase: NA • Sponsor: Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 14:03 UTC
-
New study: can proton therapy spare women from bowel problems after cancer surgery?
Symptom relief OngoingThis study compares two types of radiation therapy—proton therapy and standard intensity-modulated radiation therapy (IMRT)—given after surgery for cervical or endometrial cancer. The goal is to see if proton therapy causes fewer bowel side effects. About 120 women will fill out …
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
New speculum aims to make cancer biopsies less painful
Symptom relief ENROLLING_BY_INVITATIONThis study tests a newly designed vaginal speculum (the Bouquet Speculum) to see if it improves how doctors view the cervix, makes the biopsy procedure easier, and reduces patient discomfort. About 100 women aged 18-90 who have had a prior endometrial biopsy will take part. The g…
Phase: NA • Sponsor: Rocky Vista University, LLC • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New study tests At-Home programs to ease pain and anxiety after cancer surgery
Symptom relief OngoingThis study compares two different remote support programs to see which one helps women feel better after surgery for suspected gynecological cancer. About 160 women will take part, and researchers will measure pain, mood, and sleep quality. The goal is to find simple, at-home way…
Phase: PHASE3 • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Hand massage may offer Drug-Free relief for menstrual cramps
Symptom relief OngoingThis study tests whether a specific hand massage technique, called Su-Jok seed therapy, can reduce pain and other symptoms like nausea in people with primary dysmenorrhea (painful periods). Researchers will apply the massage to 60 female students and measure pain levels before an…
Phase: NA • Sponsor: Inonu University • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
New combo therapy aims to tame endometriosis pain in 800 women
Symptom relief OngoingThis study tests whether adding the drug elagolix to birth control pills can reduce moderate to severe pain from endometriosis. About 800 premenopausal women with surgically confirmed endometriosis will take either elagolix plus birth control or a placebo for 3 months, then all w…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
Intermittent fasting tested to ease radiation side effects in cancer patients
Symptom relief OngoingThis phase II trial tests whether time-restricted eating (intermittent fasting) can reduce side effects from radiation or chemoradiation in people with prostate, cervical, or rectal cancers. About 49 participants will either follow a time-restricted eating plan or receive standar…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Mediterranean diet tested as endometriosis pain relief
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether switching to a Mediterranean diet can reduce pelvic pain in people with endometriosis. Twenty-four participants will either follow the diet for 12 weeks or stick with their usual eating habits. Researchers will measure pain, quality of life, and gut healt…
Phase: NA • Sponsor: McMaster University • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New radiation technique aims to cut side effects for uterine cancer patients
Symptom relief OngoingThis study tests a newer type of radiation therapy called online adaptive radiotherapy (oART) for people who have had surgery for endometrial or cervical cancer. The goal is to see if using smaller treatment margins can reduce side effects while still effectively targeting any re…
Phase: PHASE1, PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
Can a phone app ease endometriosis pain? new trial tests digital therapy
Symptom relief OngoingThis study tests a smartphone app called Lyv Endo, designed to help women with endometriosis manage their symptoms. The app gives personalized advice based on each woman's symptoms. The trial will track quality of life and symptom changes in 400 women over time. It aims to see if…
Phase: NA • Sponsor: Lyv Healthcare • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Food for healing: study tests if grocery delivery helps cancer patients finish treatment
Symptom relief OngoingThis study looks at whether providing food assistance—like vouchers, grocery delivery, or a hospital food pantry—helps cancer patients finish their treatment. About 600 patients with breast cancer who struggle to afford food will be randomly assigned to one of three programs. Res…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Ice pack on the belly may ease pain after keyhole hysterectomy
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether applying an ice pack to the lower abdomen after vNOTES hysterectomy can lower pain and reduce the need for painkillers. 122 women having surgery for benign conditions will be randomly assigned to receive either standard care or standard care plus ice pack…
Phase: NA • Sponsor: Erzincan Military Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Yoga and physio may ease stress during cervical cancer radiation
Symptom relief OngoingThis study tests whether adding a special yoga and physiotherapy program to standard care can lower stress in women receiving brachytherapy for cervical cancer. About 98 women will take part. The program includes gentle movement and breathing exercises designed to be safe during …
Phase: NA • Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
New study tracks pain relief after ablation for abdominal wall endometriosis
Symptom relief ENROLLING_BY_INVITATIONThis study follows 50 people undergoing a minimally invasive procedure called percutaneous ablation to treat endometriosis in the abdominal wall. Researchers will measure how well symptoms improve and how quickly patients recover using standard pain and quality-of-life surveys. T…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Acupuncture needles aim to zap cancer brain fog
Symptom relief OngoingThis phase 2 study tests whether acupuncture can improve memory, focus, and thinking problems (often called 'chemo brain') in people who have had breast, colorectal, prostate, or gynecological cancer. About 48 participants will receive either real acupuncture or sham (fake) acupu…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Can video visits help older cancer patients? new study tests Tele-Geriatric care
Symptom relief OngoingThis study tests whether a telemedicine program is a practical way to address the unique needs of adults aged 70 and older who are receiving cancer treatment. Participants meet with a geriatric nurse via video calls over three months to discuss symptoms and aging-related concerns…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Exercise and sex ed may ease endometriosis sexual struggles
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether an 8-week program combining therapeutic exercise with sexual education can improve sexual function and self-concept in people with endometriosis. Twenty-eight participants will be split into two groups: one gets exercise plus education, the other gets exe…
Phase: NA • Sponsor: University of Valencia • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Can a blood injection ease menopause symptoms in breast cancer survivors?
Symptom relief OngoingThis phase 2 trial tests whether injecting platelet-rich plasma (PRP) into the vulva and vagina can improve symptoms of genitourinary syndrome of menopause (GSM) in breast cancer survivors. GSM causes dryness, burning, and pain, often worsened by cancer treatments. The study enro…
Phase: PHASE2 • Sponsor: University of Miami • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
New thrush treatment shows promise in early trial
Symptom relief OngoingThis study tests a product called pHyph for treating thrush (a vaginal yeast infection) in adult women. The goal is to see if pHyph reduces symptoms like itching, burning, and irritation. 48 women will either use pHyph daily for 6 days or receive no treatment, and researchers wil…
Phase: NA • Sponsor: Gedea Biotech AB • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Health education boosts Well-Being in cervical cancer patients?
Symptom relief OngoingThis study tests whether a 12-week health education program can improve lifestyle, quality of life, and mental health in 28 women with cervical cancer. Participants receive a booklet and attend meetings and social media sessions covering exercise, diet, self-esteem, and more. The…
Phase: NA • Sponsor: Federal University of Maranhao • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New injection could spare cancer patients from repeated belly drains
Symptom relief OngoingThis Phase 3 trial tests a drug called M701, given as an injection into the belly, to see if it can reduce the need for draining fluid in people with malignant ascites from advanced stomach, colorectal, or ovarian cancer. About 312 participants will either receive M701 plus drain…
Phase: PHASE3 • Sponsor: Wuhan YZY Biopharma Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Ketamine study for endometriosis pain pulled before it started
Symptom relief TerminatedThis study aimed to see if adding ketamine to standard anesthesia during endometriosis surgery could lower pain afterward. It was designed for adults with chronic pelvic pain and central sensitization, but the trial was withdrawn before enrolling any participants. No results are …
Phase: PHASE4 • Sponsor: University Hospitals Cleveland Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Seed cycling: a natural approach to ease PMS symptoms?
Symptom relief OngoingThis study looked at whether eating flax and pumpkin seeds in the first half of the menstrual cycle, and sesame and sunflower seeds in the second half, can reduce premenstrual syndrome (PMS) symptoms. 48 healthy women aged 18-35 with regular cycles took part. The goal was to see …
Sponsor: TC Erciyes University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Menopause symptom study pulled before enrolling a single patient
Symptom relief TerminatedThis study aimed to see if adding a hyaluronic acid-based vaginal moisturizer to standard vaginal estrogen therapy provides extra relief for menopause-related vaginal symptoms. It planned to enroll postmenopausal women aged 45 and older who had not used these treatments recently.…
Phase: NA • Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
New hope for breast cancer survivors: trial tests vaginal treatments for hormone therapy side effects
Symptom relief OngoingThis study tests four different vaginal treatments (estrogen, DHEA, estrogen with probiotics, and a moisturizer) in 160 breast cancer patients who have vaginal atrophy due to hormone therapy. The goal is to see which treatment best relieves symptoms like dryness and pain, and imp…
Phase: PHASE4 • Sponsor: University Hospital, Ghent • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
SISTER study: peer support may boost cancer treatment completion
Symptom relief OngoingThis study tests whether group or one-on-one peer support helps Black patients with endometrial cancer complete their treatment and feel less isolated. About 252 participants will be randomly assigned to group support, one-on-one peer calls, or usual care. The main goal is to see…
Phase: NA • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Remote exercise and education program aims to boost Well-Being in older cancer patients
Symptom relief OngoingThis study tests whether a 12-week program of online chair-based exercise and health education, combined with a geriatric assessment, is feasible and helpful for adults aged 65+ with certain cancers and their support persons. The program is delivered remotely, and the study will …
Phase: NA • Sponsor: Martine Puts • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Can a Stress-Busting app boost baby chances?
Symptom relief OngoingThis pilot study tests whether an online stress management program called Stress Free Now can lower stress and possibly increase pregnancy rates in women aged 18-34 who have been trying to conceive for 6-12 months. Forty women will be randomly assigned to either the program or a …
Phase: NA • Sponsor: Courtney D.Lynch, PhD MPH • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Good bacteria vs. bad cramps: probiotics tested for menstrual relief
Symptom relief OngoingThis study tests whether taking a daily probiotic supplement can reduce menstrual pain and premenstrual symptoms in women. 150 women with moderate-to-severe period pain will take either a high or low dose of probiotics or a placebo for four menstrual cycles. Researchers will trac…
Phase: NA • Sponsor: Glac Biotech Co., Ltd • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
New study pits elagolix against birth control pills for endometriosis pain relief
Symptom relief ENROLLING_BY_INVITATIONThis study compares two treatments—elagolix and oral contraceptive pills (OCPs)—to see which better reduces pelvic pain from endometriosis. About 90 women aged 18-45 with confirmed endometriosis will report their pain levels over 24 weeks. The goal is to help doctors choose the b…
Phase: PHASE4 • Sponsor: Pak Emirates Military Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Simple relaxation methods show promise for PMS relief
Symptom relief OngoingThis study looks at whether combining two relaxation techniques—Benson relaxation and Jacobson progressive muscle relaxation—can reduce symptoms of premenstrual syndrome (PMS) in women aged 18 to 30. Fifty-six female students with PMS will be split into three groups: one using Be…
Phase: NA • Sponsor: University of Health Sciences Lahore • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
New drug may keep chemo on track for lung, ovarian, and breast cancer patients
Symptom relief OngoingThis study tests whether romiplostim can prevent chemotherapy delays or dose reductions caused by low platelet counts in people with lung, ovarian, or breast cancer. About 145 adults will receive either romiplostim or a placebo alongside their chemotherapy. The goal is to help pa…
Phase: PHASE3 • Sponsor: Amgen • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
Soundwave therapy shows promise for chemo nerve damage
Symptom relief OngoingThis study tests a device called SensoniQ® Treatment Station that uses low frequency soundwaves to prevent or reduce nerve pain caused by chemotherapy in people with gynecologic cancer. The trial includes 80 participants, some starting chemo and others with lasting nerve pain. Re…
Phase: NA • Sponsor: Augusta University • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Can a simple assessment make chemotherapy safer for seniors?
Symptom relief OngoingThis study tests whether a personalized care plan, based on a geriatric assessment, can reduce severe side effects in older adults (65+) starting chemotherapy for common cancers. Participants are randomly assigned to receive the assessment-driven plan plus usual care, or usual ca…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Breathing and pelvic floor exercises may offer Drug-Free period pain relief
Symptom relief ENROLLING_BY_INVITATIONThis study looks at whether adding pelvic floor muscle exercises to deep breathing can help reduce pain during periods in women with primary dysmenorrhea. Forty women will be split into two groups: one doing both exercises, the other only deep breathing. Researchers will measure …
Phase: NA • Sponsor: Istanbul Gelisim University • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Mind over scalpel: Self-Hypnosis may ease Post-Surgery pain for cancer patients
Symptom relief OngoingThis study looks at whether listening to a self-hypnosis audio before surgery can help women with gynecologic cancer feel less pain and recover faster. About 152 patients having surgery for cancers of the female reproductive system will be randomly assigned to either usual care o…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Mushroom extract tested to ease chemo side effects in ovarian cancer
Symptom relief OngoingThis pilot study tests whether a supplement called AHCC, made from cultured mushroom mycelia, can improve quality of life for ovarian cancer patients receiving standard chemotherapy. About 20 participants will take either AHCC or a placebo during their treatment. The main goal is…
Phase: PHASE2 • Sponsor: University of California, Davis • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
THC pain study for endometriosis pulled before start
Symptom relief TerminatedThis study aimed to see if a synthetic THC pill (Marinol) could safely reduce chronic pelvic pain in women with endometriosis. It planned to enroll up to 75 women aged 18-64 and give them THC or a placebo for 8 weeks. However, the study was withdrawn before any participants were …
Phase: PHASE2 • Sponsor: Baylor College of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Phone therapy shows promise for depression in ovarian cancer patients
Symptom relief OngoingThis study looks at whether weekly phone counseling can help identify and treat depression in women with ovarian, peritoneal, or fallopian tube cancer. About 409 participants will either receive phone counseling or standard care with resource lists. The goal is to see which appro…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Home workouts may help endometrial cancer survivors shed pounds
Symptom relief OngoingThis study tests whether a home-based weight loss program, with or without resistance training, is practical for endometrial cancer survivors. Fifteen participants will follow a program using a workbook, fitness tracker, and coaching calls. The goal is to see if they can lose wei…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
New pill could ease endometriosis pain without needles
Symptom relief OngoingThis Phase 3 trial tests an oral drug called KLH-2109 for pelvic pain in 288 women with endometriosis. Participants receive either KLH-2109 or a standard injection (leuprorelin acetate) for 12 weeks. The goal is to see if the new pill works as well as the injection in reducing da…
Phase: PHASE3 • Sponsor: Kissei Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
Blood test plus genetic score may sharpen recurrence prediction in endometrial cancer
Knowledge-focused OngoingThis observational study looks at whether combining a blood test that detects tumor DNA (ctDNA) with a new genetic risk score can better predict if endometrial cancer will come back after surgery. Researchers will follow 52 women who had a hysterectomy for endometrial cancer, col…
Sponsor: Guizhou Provincial People's Hospital • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
HPV Vaccine's Long-Term effects under the microscope in costa rica
Knowledge-focused OngoingThis study follows over 8,600 women in Costa Rica who received the HPV vaccine (types 16 and 18) years ago, plus unvaccinated controls, to see how well the vaccine protects over time. Researchers are checking for cervical lesions, immune markers, and any increase in infections fr…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Blood test may help cancer patients avoid nerve damage from chemo
Knowledge-focused TerminatedThis pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Teens with PCOS may face hidden liver risks, study investigates
Knowledge-focused TerminatedThis study looks at whether teenagers and young adults with Polycystic Ovary Syndrome (PCOS) have more fat in their liver than those without PCOS. Researchers will use advanced imaging and tests to measure liver fat, insulin resistance, and cholesterol problems in 80 participants…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Hidden pelvic vein issues may sabotage leg vein surgery, study warns
Knowledge-focused OngoingThis study looks at how often pelvic congestion syndrome (a condition where veins in the pelvis become enlarged and painful) occurs in women who are about to have a standard procedure for leg varicose veins. Researchers want to know if having this pelvic condition affects how muc…
Sponsor: Chengdu University of Traditional Chinese Medicine • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
AI-Guided radiation may shield ovaries in young cancer patients
Knowledge-focused OngoingThis study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Simple blood tests may help predict ovarian cancer treatment success
Knowledge-focused OngoingThis study investigates whether certain blood-based markers, such as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and the CA-125 elimination rate (KELIM score), can predict survival and surgical outcomes in women with advanced ovarian cancer. Researcher…
Sponsor: Aya Ahmed Nasser • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Virtual peer mentoring aims to boost cervical cancer screening in ethiopian HIV clinics
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests whether a virtual training and peer-mentoring program called Project ECHO can help healthcare providers in Ethiopia improve cervical cancer screening and treatment for women living with HIV. The program focuses on using HPV self-sampling, a simpler screening meth…
Phase: NA • Sponsor: Albert Einstein College of Medicine • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
New study aims to uncover hidden heart risks in women
Knowledge-focused OngoingThis pilot study is testing whether it's possible to run a larger study that focuses on heart disease in women. Researchers will gather information from 176 women aged 25-55 in Ontario who have had certain female-specific health issues like pre-eclampsia, gestational diabetes, or…
Phase: NA • Sponsor: Ottawa Heart Institute Research Corporation • Aim: Knowledge-focused
Last updated Jul 03, 2026 00:00 UTC
-
Gene therapy patients monitored for 15 years to spot hidden side effects
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows up to 1,000 adults who previously received gene therapy in a National Cancer Institute study. Researchers will contact participants yearly for up to 15 years to check for any long-term side effects, such as new cancers or nerve problems. No new treatments are g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
NIH launches biobank to unlock DNA secrets of Women's cancers
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects blood, urine, and tumor tissue from 500 adults with breast, ovarian, or uterine cancer, plus some of their relatives. The goal is to create a repository of samples for future research on DNA changes that drive these cancers. Participants give samples during ro…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
New test could predict immunotherapy success from live tumor samples
Knowledge-focused OngoingThis observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New study aims to improve cervical cancer monitoring for HIV-Positive women
Knowledge-focused OngoingThis observational study follows 168 women living with HIV in Zimbabwe who have been treated for cervical pre-cancer. Researchers want to learn how often the disease comes back and whether HPV or DNA tests can predict recurrence. Participants will be monitored every six months fo…
Sponsor: University of Bern • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
New study tracks menstrual changes in young breast cancer patients
Knowledge-focused OngoingThis study follows 810 young women aged 18-45 with early-stage breast cancer to understand how treatment affects their menstrual cycles and quality of life. Participants complete questionnaires every six months for up to 42 months. The goal is to identify factors that lead to ear…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Frozen embryo transfer: one extra day could boost success rates
Knowledge-focused TerminatedThis study looks at whether transferring a frozen embryo on day 6 or day 7 of progesterone treatment leads to more live births. It includes 316 women aged 18-43 who have at least one high-quality, genetically normal embryo. Researchers will track pregnancy and miscarriage rates t…
Phase: PHASE1 • Sponsor: ART Fertility Clinics LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Massive 30-Year Women's health study reveals hidden disease links
Knowledge-focused OngoingThis long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Does surgery spread cervical cancer cells? new study investigates
Knowledge-focused OngoingThis study looks at whether surgery for early-stage cervical cancer causes tumor cells to enter the bloodstream, which might explain higher recurrence rates seen with certain surgical methods. Researchers will take blood samples from 20 women during their operation to detect circ…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Scientists seek better way to classify uterine condition
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to improve how doctors classify adenomyosis, a condition that causes heavy bleeding and pain. Researchers will compare ultrasound, MRI, and tissue results from 32 women aged 35-55 who are scheduled for hysterectomy. The goal is to link imaging findings with sympto…
Sponsor: Kafrelsheikh University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug triapine tested in rare uterine cancer before surgery
Knowledge-focused OngoingThis early-phase trial is testing the drug triapine in 12 women with a rare and aggressive type of uterine cancer called uterine serous adenocarcinoma. Participants receive a single dose of triapine before their scheduled hysterectomy, and researchers analyze tissue samples to se…
Phase: EARLY_PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Lost in translation: study probes language barriers in gynecologic cancer care
Knowledge-focused OngoingThis study gives questionnaires to patients, interpreters, and healthcare professionals to understand how language and cultural differences impact care for women with gynecologic cancer. The goal is to identify barriers and improve the patient experience. About 45 people will tak…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Keytruda immune response trial aims to unlock cancer clues
Knowledge-focused OngoingThis phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Gene mutations may explain why some endometriosis treatments fail
Knowledge-focused OngoingThis study looks at whether certain genetic changes (mutations) in endometriosis tissue are linked to resistance to progesterone therapy. Researchers will compare tissue samples from 135 women with and without endometriosis. The goal is to better understand why some cases don't r…
Sponsor: Johns Hopkins University • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Can we predict who will get nerve damage from chemo?
Knowledge-focused OngoingThis study aims to find out why some cancer patients develop nerve damage (tingling or numbness in hands and feet) from taxane chemotherapy. Researchers will track over 1,300 people with breast, lung, or ovarian cancer to see how age, gender, and other factors affect their risk. …
Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Could a stopped period warn of heart trouble? mayo clinic investigates
Knowledge-focused OngoingThis study looks at young women with hypothalamic amenorrhea (missed periods for months or years) to see if their condition is linked to early signs of heart disease. Researchers will use Fitbit trackers and questionnaires to measure stress, activity, and diet, along with blood t…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Can we predict who will benefit from immunotherapy? new study aims to find out.
Knowledge-focused OngoingThis study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New study aims to map ovarian cancer in unprecedented detail
Knowledge-focused OngoingThis study looks at whether combining PET/MRI scans with blood and tumor tissue tests can create a detailed profile of high-grade serous ovarian cancer. The goal is to better predict how tumors respond to treatment, which could help doctors personalize care. The study involves 10…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Estrogen patches tested for brain effects in eating disorders
Knowledge-focused OngoingThis study looks at whether estrogen patches can improve mental flexibility and reward processing in young women (ages 14-35) with eating disorders linked to low estrogen. About 120 participants will receive either estrogen patches or placebo for 12 weeks. The goal is to understa…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
700 women followed for over a decade to see which fibroid treatments last longest
Knowledge-focused OngoingThis study follows about 700 women for up to 12 years after they had a uterine-sparing fibroid treatment, such as myomectomy or uterine artery embolization. Researchers want to see how long these treatments last before another procedure is needed, and how women's symptoms and qua…
Sponsor: Henry Ford Health System • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Can mitochondrial energy predict resilience in older cancer patients?
Knowledge-focused TerminatedThis study looks at whether older adults with gynecologic cancer are willing to complete physical and cognitive tests before and after treatment. Researchers will also take small muscle and blood samples to study how cell energy relates to resilience. The goal is to see if this k…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC
-
Massive ovarian cancer database reveals treatment trends across france
Knowledge-focused TerminatedThis study collects information from over 13,000 women treated for ovarian cancer at 18 French cancer centers. Researchers will look at patient details, tumor types, and treatments given to see how care has evolved since 2011. The goal is to understand what treatments are used an…
Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Can combining HPV tests with family planning save more women from cervical cancer?
Knowledge-focused OngoingThis large study in Mozambique is testing whether offering HPV self-testing alongside voluntary family planning services increases the number of women who get screened for cervical cancer. Over 9,000 women aged 30–49 or living with HIV are taking part. The goal is to see if integ…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Kidney transplant patients' immune response to common virus tracked after drug switch
Knowledge-focused OngoingThis study follows 28 kidney transplant recipients who are switching from one anti-rejection drug (anticalcineurin) to another (belatacept). Researchers want to see how this change affects the immune system's ability to fight the common CMV virus. Participants will have blood tes…
Sponsor: University Hospital, Rouen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Rare surgery for recurrent cancer: how does it affect quality of life?
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 21 patients who had a very extensive surgery called pelvic exenteration for recurrent gynecologic cancer. The goal is to understand how the surgery affects their quality of life and sexuality using standard questionnaires. The results will help doctors better p…
Sponsor: Tampere University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Gene therapy safety check: 400 cancer patients monitored for years
Knowledge-focused ENROLLING_BY_INVITATIONThis study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Can an AI coach help teens manage period pain better than a teacher?
Knowledge-focused OngoingThis study tests three ways to teach teen girls about managing period pain and hygiene: an AI-powered mobile app, face-to-face classes, and a brochure. About 120 girls aged 14-17 will take part, and researchers will check their knowledge and habits after 4 and 8 weeks. The goal i…
Phase: NA • Sponsor: Cumhuriyet University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Uterine cancer survivors: how does treatment affect daily life?
Knowledge-focused OngoingThis study looks at pelvic floor problems and quality of life in people who survived uterine cancer. Researchers will use questionnaires to gather information from about 310 survivors treated with surgery at MD Anderson between 2006 and 2017. The goal is to better understand how …
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
New breathing technique tested in robotic cancer surgery
Knowledge-focused TerminatedThis study aimed to compare a newer breathing machine method (APRV) with the standard method (CMV) during anesthesia for robotic gynecologic or genitourinary cancer surgery. The goal was to find the best settings to help patients' lungs work well during the procedure. However, th…
Phase: NA • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New online program aims to help women with missed periods
Knowledge-focused OngoingThis study tests a 10-week online education program for women with functional hypothalamic amenorrhea (FHA), a condition where periods stop due to stress, low energy, or excessive exercise. The program provides self-guided lessons on stress, nutrition, and exercise. Researchers w…
Phase: NA • Sponsor: Karolinska Institutet • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Massive cancer survival study launched in russia
Knowledge-focused OngoingThis study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…
Sponsor: N.N. Petrov National Medical Research Center of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Family genetic testing could prevent ovarian cancer
Knowledge-focused OngoingThis study looks at whether offering genetic testing to family members of people with hereditary breast and ovarian cancer syndrome helps more relatives learn about their own cancer risk. Researchers will follow 118 participants and their relatives to see how many choose to get t…
Sponsor: NYU Langone Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Massive biobank aims to unlock Cancer's secrets
Knowledge-focused OngoingThis study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Does your income affect your cancer care? new study investigates
Knowledge-focused OngoingThis study analyzes data from over 45,000 people diagnosed with colon or ovarian cancer in England between 2016 and 2017. Researchers are looking for differences in how quickly people are diagnosed and what treatments they receive, based on their socioeconomic status. The goal is…
Sponsor: University of Hull • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Survivors share their stories to shape better cancer Follow-Up care
Knowledge-focused OngoingThis study looks at how gynecological cancer survivors feel and function after finishing their main treatment. About 1,100 people who are currently cancer-free will answer questionnaires about their quality of life, anxiety, sexual health, and more. The goal is to learn what matt…
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Oxygen clues could unlock better cervical cancer treatment
Knowledge-focused OngoingThis study aims to find biological markers (biomarkers) that show which cervical cancers have low oxygen levels, making them harder to treat with standard radiation. About 30 patients with advanced cervical cancer will have special MRI scans and tumor biopsies before and during t…
Sponsor: University of Manchester • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New study tracks pelvic changes after radiation in women with pelvic cancer
Knowledge-focused OngoingThis study follows 72 women with pelvic cancers (anal, cervical, endometrial, rectal, vaginal, or vulvar) who are receiving radiation therapy. Researchers will use pelvic exams and surveys to measure changes in vaginal health, sexual function, and quality of life over two years. …
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Study questions best surgery for High-Risk endometrial cancer
Knowledge-focused OngoingThis study looks back at 700 patients with endometrial cancer to compare two surgical approaches: minimally invasive surgery (laparoscopy) and open surgery (laparotomy). The goal is to see which method is safer and leads to better long-term outcomes, especially for patients at hi…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Ovarian tumor genes may reveal who needs stronger treatment
Knowledge-focused OngoingThis study examines genetic mutations in 20 people with serous borderline ovarian tumors, a low-risk type of ovarian growth. Researchers compare tumors with and without implants (spread) to see if certain gene changes predict a higher chance of recurrence. The goal is to learn wh…
Sponsor: Universitair Ziekenhuis Brussel • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists dig into the vaginal microbiome to unlock secrets of recurrent yeast infections
Knowledge-focused OngoingThis study looks at 120 Canadian women to understand why some get repeated yeast infections while others don't. Researchers will compare the vaginal yeast and bacteria of women with their first infection, those with recurrent infections, and those with yeast but no symptoms. Part…
Phase: EARLY_PHASE1 • Sponsor: University of Manitoba • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Electronic surveys tested for tracking radiation side effects in gynecologic cancer
Knowledge-focused OngoingThis study aims to see if it is practical to use electronic questionnaires to measure patient-reported symptoms before, during, and after radiation treatment for gynecologic cancer. About 100 English-speaking adults receiving radiation at UNC will participate. The main goal is to…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Antibiotics for early water break study halted before start
Knowledge-focused TerminatedThis study aimed to see if giving antibiotics to pregnant people whose water broke very early (before 22 weeks) could delay delivery and improve baby health. It was planned for those with a single baby and recent membrane rupture. However, the study was withdrawn before enrolling…
Phase: PHASE4 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
5,000 women join quest to unravel Endometriosis-Fertility link
Knowledge-focused OngoingThis study follows 5,000 women with and without endometriosis who are undergoing IVF treatment. Researchers will track pregnancy and birth rates, and analyze biological samples to understand how endometriosis affects fertility. The goal is to gather evidence that could lead to be…
Sponsor: The Second Hospital of Shandong University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
New tool could help doctors master colon polyp removal faster
Knowledge-focused OngoingThis study looks at how doctors in training learn to remove colon polyps using a special tool called EMR-STAT. Researchers will track 42 trainees from multiple centers to see when they become skilled enough. The goal is to set clear standards for training, which could lead to saf…
Sponsor: AdventHealth • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Massive ovarian cancer screening trial tests whether early detection cuts deaths
Knowledge-focused OngoingThis study enrolled over 78,000 women to see if regular screening with ultrasound and blood tests can lower the number of deaths from ovarian cancer. Participants were randomly assigned to either receive screening or usual care. The goal is to find out if catching the cancer earl…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Fibroid treatment showdown: which procedure stands the test of time?
Knowledge-focused OngoingThis nationwide registry follows 578 women with uterine fibroids who choose either radiofrequency ablation (Acessa) or myomectomy. Researchers track symptom changes, quality of life, and need for repeat treatment over three years. The goal is to understand which procedure provide…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
New genetic panel could personalize cancer treatment
Knowledge-focused OngoingThis study enrolls 4,000 people with breast, ovarian, or colorectal cancer to test a comprehensive genetic panel. The panel looks for inherited cancer risks and tumor mutations that may affect drug sensitivity. Researchers aim to validate these genetic findings to potentially gui…
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New imaging dye could reveal hidden oxygen levels in cervix tumors
Knowledge-focused OngoingThis study is testing whether a special PET scan dye called 18F-FAZA can measure low oxygen levels (hypoxia) in cervix cancer tumors. About 30 adults with cervix cancer will receive the dye before starting standard treatment with radiation and chemotherapy. The goal is to see if …
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Ovarian cancer breakthrough? tumor slices could reveal best drug for each patient
Knowledge-focused OngoingThis study tests whether thin slices of ovarian tumors, kept alive in the lab, can predict how a patient will respond to chemotherapy. Researchers will take tumor samples from 48 women with advanced ovarian cancer during surgery. They will then expose the slices to different drug…
Phase: NA • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New website aims to ease tough fertility choices for women with cancer
Knowledge-focused OngoingThis study tests a decision aid website called Pathways to Fertility for women newly diagnosed with cancer who may face infertility from treatment. About 130 women will use the website or receive standard care to see if it helps them make more informed and less conflicted decisio…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Tiny study probes tumor oxygen levels in cervical cancer
Knowledge-focused OngoingThis study measures oxygen levels inside cervical cancer tumors during a type of radiation called brachytherapy. Ten adult patients with cervical cancer will have tiny oxygen sensors placed in their tumors during the procedure. The goal is to see if oxygen levels relate to how we…
Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists hunt for hidden genes behind rare pregnancy moles
Knowledge-focused OngoingThis study aims to find the genetic changes that cause some women to have repeated molar pregnancies (abnormal growths in the womb). Researchers will analyze DNA from blood and tissue samples of up to 100 women and their relatives. The goal is to discover new genes linked to this…
Sponsor: Baylor College of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Blood test may personalize ovarian cancer care after surgery
Knowledge-focused OngoingThis study is testing whether a blood test that looks for tiny bits of tumor DNA (called ctDNA) can help doctors decide who needs extra treatment after ovarian cancer surgery. Researchers will analyze stored blood samples from 50 patients taken before and after surgery. The goal …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New imaging study peers inside tumors without treatment
Knowledge-focused OngoingThis study aims to learn more about how oxygen, metabolism, and blood supply work in high-grade brain tumors and cervical cancers. About 20 adults with these cancers will receive special PET and MRI scans. No treatment is given; the goal is to better understand tumor biology.
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Ovarian cancer drug trial aims to unlock DNA secrets before surgery
Knowledge-focused OngoingThis early-phase trial is testing a drug called adavosertib in 38 people with advanced ovarian, fallopian tube, or peritoneal cancer. Participants take the drug for up to 28 days before their scheduled surgery. Researchers will compare tumor DNA before and after treatment to see …
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Can your genes predict chemo nerve pain?
Knowledge-focused OngoingThis study looks at how a person's genes and medical history might help predict nerve damage caused by chemotherapy. Researchers will follow 300 people with certain cancers who are scheduled for specific chemo drugs. The goal is to find patterns that could help prevent or reduce …
Sponsor: National Cheng-Kung University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
What makes ovarian cancer survivors thrive? scientists investigate diet, mood, and support
Knowledge-focused OngoingThis study looks at women who have lived at least seven years after an ovarian cancer diagnosis. Researchers want to learn how diet, exercise, emotions, and social support may be linked to long-term survival. Participants fill out questionnaires and take part in interviews about …
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Study explores fertility hopes after cancer in young women
Knowledge-focused OngoingThis study surveys women aged 18-45 diagnosed with gynecological or breast cancer to understand how they think about having children after treatment. Researchers aim to gather insights that could help future patients and survivors make informed choices about cancer treatment and …
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New MRI dye could reveal ovarian Cancer's true aggressiveness
Knowledge-focused TerminatedThis study is testing whether a special MRI contrast agent, called hyperpolarized 13-C pyruvate, can help doctors see how aggressive ovarian cancer is. About 30 women at high risk for ovarian cancer will be scanned. The goal is to improve early detection, not to treat the disease…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Scientists hunt for genes that control puberty
Knowledge-focused OngoingThis study aims to find the genes involved in inherited reproductive disorders, such as delayed or early puberty and low hormone levels. Researchers will analyze genetic data from 600 participants with these conditions. The goal is to identify genetic variations that may explain …
Sponsor: Stephanie B. Seminara, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New study explores less drastic option for deadly pregnancy disorder
Knowledge-focused OngoingThis pilot study tests whether leaving the placenta in place after delivery (conservative management) is a safe and effective alternative to hysterectomy for women with placenta accreta spectrum, a condition where the placenta grows too deeply into the uterine wall. Four particip…
Phase: NA • Sponsor: University of Utah • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New mastitis symptom scales put to the test
Knowledge-focused OngoingThis study evaluates two new methods—the M-Score and BISSI—for assessing symptom severity in non-lactational mastitis, a breast inflammation condition not related to breastfeeding. Researchers will enroll 320 women aged 18-65 with confirmed non-lactational mastitis to see if thes…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Cancer gene hunt: 21,000 Patients' DNA scoured for clues
Knowledge-focused OngoingThis study examines DNA from over 21,000 cancer patients in New York to find gene changes linked to several cancers, including breast, colon, and lung. Researchers will compare these genes to those from healthy people to spot differences. The goal is to generate ideas for future …
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
New study aims to better classify small newborns for tailored nutrition
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at 290 full-term babies who were small at birth due to intrauterine growth restriction (IUGR). Researchers will measure their body fat and muscle using a special machine, and track their growth and feeding for three months. The goal is to find different types of …
Sponsor: Centro Hospitalar de Lisboa Central • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
New study hopes to outsmart pancreatic cancer by gathering clues
Knowledge-focused OngoingThis study collects health information and test results from 317 people at high risk for pancreatic cancer, including those with cysts, genetic syndromes, or other risk factors. Researchers aim to build a database to find better ways to detect the disease early or prevent it. No …
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Scientists hunt for genetic markers in ovarian, uterine, and cervical cancers
Knowledge-focused OngoingThis study is collecting blood and tumor samples from 300 people suspected of having ovarian, endometrial, or cervical cancer. Researchers will analyze the samples to find genetic changes that might predict how the cancer behaves. The goal is to better understand these cancers, n…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Can ovarian freezing help girls with turner syndrome have children later?
Knowledge-focused OngoingThis study looks at freezing ovarian tissue in girls with Turner syndrome, a condition that often causes early ovary failure and infertility. Researchers want to find out which patients are most likely to have healthy eggs in their tissue by checking their genes, hormones, and me…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Can your diet and genes predict uterine cancer?
Knowledge-focused OngoingThis study looks at how diet, lifestyle, and genetics influence the risk of endometrial cancer. Researchers will compare women who have or had the cancer with those who do not, using surveys and genetic analysis. The goal is to identify factors that may increase or decrease risk,…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New web tool aims to help cancer patients make sense of their genes
Knowledge-focused OngoingThis study tests a web-based education tool called HOPE-Genomics that teaches cancer patients about their genetic test results. About 465 adults with breast, colorectal, lung, ovarian, pancreatic, or prostate cancer are taking part. The goal is to see if the tool helps patients r…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Hidden plastic in fertility cells? new study investigates.
Knowledge-focused OngoingThis study checks whether tiny plastic particles, called microplastics, can be found in the cells and fluid around eggs in women undergoing fertility treatment (ICSI). Researchers will collect samples from 100 women to see if microplastics are present. The goal is simply to find …
Sponsor: Infertility Treatment Center Dortmund • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Less invasive staging for endometrial cancer put to the test
Knowledge-focused OngoingThis phase 3 trial compares a less invasive sentinel node biopsy approach to standard staging methods in 262 women with early-stage endometrial cancer at intermediate or high risk of recurrence. The goal is to see if the sentinel node policy reduces surgical complications while s…
Phase: PHASE3 • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Resident's journey to master scarless hysterectomy under the microscope
Knowledge-focused OngoingThis study watches a single gynecology resident as they learn to perform a hysterectomy through the vagina using a special camera, leaving no belly scars. The goal is to see how quickly the resident improves, measuring surgery time and any complications. Nineteen women with benig…
Sponsor: Cukurova University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Can a brochure or peer talk boost vulvar self-exam habits?
Knowledge-focused OngoingThis study looks at whether a peer-led lesson or an educational brochure helps female nursing students learn about and practice vulvar self-examination. About 105 students will be split into three groups: one gets a peer lesson, one gets a brochure, and one gets no special teachi…
Phase: NA • Sponsor: Yeditepe University • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Study aims to predict which preterm babies with growth problems face the highest health risks
Knowledge-focused OngoingThis observational study looks at preterm babies born with early fetal growth restriction (poor growth in the womb) to understand how factors like mother's health and blood flow changes in the womb affect the baby's health after birth. Researchers will compare 200 such babies to …
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New program aims to boost genetic testing in cancer families
Knowledge-focused OngoingThis study looks at whether a website and a genetic family navigator can help more relatives of people with hereditary cancer get genetic testing. About 205 participants will use the online hub and work with a navigator to learn about their cancer risk. The goal is to see if this…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New study aims to predict cancer return in Low-Risk patients
Knowledge-focused OngoingThis study looks at whether molecular testing and lymph node mapping can help predict if low-risk endometrial cancer will return after surgery. About 518 patients with early-stage, low-grade cancer will be followed for two years. The goal is to improve follow-up care by identifyi…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
MRI tracking could make cervix cancer radiotherapy safer
Knowledge-focused OngoingThis study tracks how the tumor and nearby organs move during radiotherapy for cervix cancer. By taking many MRI scans during treatment, researchers hope to better target the tumor and spare healthy tissue. The goal is to reduce side effects and improve outcomes. The study involv…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Can tumor oxygen levels predict radiation success in cervical cancer?
Knowledge-focused OngoingThis study looks at whether oxygen levels and internal pressure in cervical tumors can help predict how well radiation therapy works. Researchers measured these factors in 346 patients with cervical cancer before and during treatment. The goal is to understand why some tumors res…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
New study maps normal heart function in newborns
Knowledge-focused OngoingThis study observes heart function in 216 newborns born at 35 weeks or later. Researchers will use ultrasound to measure how the heart relaxes and fills with blood, creating normal reference values. They will also check if factors like mother's health or birth conditions affect h…
Sponsor: University College Cork • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New study investigates why some women with adenomyosis suffer more pain
Knowledge-focused OngoingThis study looks at how the nervous system may become overly sensitive (central sensitization) in women with adenomyosis, a condition where uterine tissue grows into the muscle wall. Researchers will follow 1,200 women aged 18-50 for 12 months to see how common this sensitivity i…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Oxygen levels in cervical tumors may predict treatment success
Knowledge-focused OngoingThis study looks at how low oxygen levels and fluid pressure inside cervical cancer tumors relate to how well radiation therapy works. Researchers will measure these factors in 500 patients before and during treatment. The goal is to find the best way to identify which patients m…
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Can we predict who recovers best from radical cancer surgery?
Knowledge-focused OngoingThis study follows women who have had pelvic exenteration—a surgery removing the lower colon, rectum, and bladder—for gynecologic cancers like cervical or endometrial cancer. Researchers want to see if factors like tumor size or surgery type affect complications, quality of life,…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Can a Mid-Treatment scan make radiation smarter?
Knowledge-focused OngoingThis study is testing whether doing a special PET scan during radiation treatment can help doctors adjust the plan to better target tumors and spare healthy tissue. It involves 90 adults with cervical, vulvar, esophageal, or anal cancer. The goal is to see if this approach improv…
Phase: PHASE2 • Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New study peers inside ovarian cancer after chemo
Knowledge-focused OngoingThis study looks at people with advanced ovarian cancer who have a second look laparoscopy after finishing their first chemotherapy. Doctors want to compare health outcomes between those who still have small amounts of cancer left and those who don't. They also want to see if thi…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC